Privately-Held Companies with Emerging Medical Technologies



EMT (EMERGING MEDICAL TECHNOLOGIES)® DATABASE


1194 Companies to Date | + Regular Updates | Coverage through 2011



 


The Emerging Medical Technologies (EMT) Database is an online tool for strategic marketing, market research, business development and investment executives seeking discreet and detailed business, market, and competitive intelligence on privately-held companies developing disruptive technologies.

This database currently includes 1194 companies and includes regular updates.

LSI leverages multiple, exclusive data streams to feed this robust database, including:

  • An exclusive license to record the presentations and executive summaries for presenting companies at the prestigious annual Medtech Insight/Elsevier In3 West, In3 East, In3 Medical Device Summit, and In3 Europe meetings (approximately 130 companies per year)
  • CEO presentations and executive summaries from LSI’s quarterly EMT Spotlight meetings (approximately 130 companies per year)
  • Ongoing in-house research efforts (approximately 140 companies per year)

You get access to existing content, database additions, and updates for the duration of your subscription.

This database is the premier tool for identifying, tracking, partnering with, investing in, or reacting to, emerging companies in the space.


Company Overviews:


Data includes:
  • Key Executive
  • Financing Status and Needs
  • Revenue
  • Development Status
  • Strategic Partnering Needs
  • Contact Info
  • Year Established
  • Website
  • + More
  Executive Summaries:

Data includes:
  • Company Overview (structure, size, year founded, etc)
  • Technology Details
  • Target Markets
  • Competitive Landscape and Differentiation
  • Financial Summary and Sales Forecasts
  • Financing & Partnering Needs
  • IP Position & Status
  • Management Team Overview
  • + More
  CEO Presentations:


Data includes:
  • 10-15 minute slides and corresponding audio
  • Investor/Partner/Business related content -- not product demos or infomercial style videos readily available in the public domain
  • Coverage of all past and future IN3 Conferences

* Depth of coverage varies for each company.
** Coverage includes regular updates on new, emerging companies.

Comprehensive Search Features Include:

Keyword & Exact Phrase Searching:

  Search By Medical Market:


Search By Conference:


 
Search By Company Name:

Search By Region:
   
EMERGING MEDICAL TECHNOLOGIES DATABASE

In addition to the companies covered on the In3 conference circuit, we reveal new companies to you via our active in-house research efforts and quarterly EMT Spotlight meetings.

Technology descriptions for companies currently covered as of 09/03/10 include:

  • Company 1 - Effective, reliable use of autologous adult stem cells (ASCs) to enhance fusion in spine and orthopedic surgery
  • Company 2 - Fail-safe and inexpensive system that employs a technology to prevent errors in the intravenous administration of drugs and blood transfusion
  • Company 3 - Device that applies gentle pulsing forces, in combination with standard orthodontics, to move teeth faster through accelerated bone remodeling
  • Company 4 - Forward-looking intravascular ultrasound (FLIVUS) catheters that can determine correct stent size and placement through a field of view which extends beyond the catheter tip
  • Company 5 - Lightweight and portable system with unsurpassed fluid balance accuracy for blood purification and fluid management
  • Company 6 - Single-use, disposable \"sensing embedded\" surgical glove 1-to accurately map cervical length/dilatation during pre-term/full-term labor, 2-as a tool in general surgery, and 3-as a tool in telemedicine
  • Company 7 - Reagents for use in non-invasive MRI, PET, and optical imaging
  • Company 8 - Non-invasive device that acts as a robotic physical therapist for treating chronic head and neck pain
  • Company 9 - Next-generation diagnostic platform for personalized medicine
  • Company 10 - Patient monitoring system providing real-time continuous information via four physiological parameters - sensed at the tissue level, reflecting the patient\'s systemic metabolic state
  • Company 11 - Prevention and treatment of osteoporosis-related fractures
  • Company 12 - High-performance, inexpensive, single-use disposable dry-powder inhaler (DPI) suitable for hospital and OTC use, as well as acute applications
  • Company 13 - Fibroblast growth factor (FGF) variants for therapeutic and reagent/cell expansion applications with a commercial focus on articular cartilage repair and regeneration
  • Company 14 - Bioceramics for the treatment of post-myocardial infarction (MI), mitral valve regurgitation, applications to coronary and peripheral stents, and other technologies
  • Company 15 - Cost-effective, laser-based antimicrobial treatments for Chronic Rhinosinusitis (CRS)
  • Company 16 - Modular, 3D, real-time, stereoscopic vision and recording systems to change the surgical paradigm from 2D to 3D-HD stereoscopic vision for minimally invasive surgery (MIS)
  • Company 17 - Next-generation infusion pump platform to bring new standards of accuracy and ease-of-use to the hospital and homecare markets
  • Company 18 - Non-hormonal, one-size-fits-all intravaginal contraceptive ring
  • Company 19 - Single-use high-definition (HD) surgical camera that will provide high-quality HD imaging at a fraction of the price of current market leading HD cameras
  • Company 20 - Endoscopic accessory devices that fill unmet needs in the field of gastrointestinal (GI) endoscopy
  • Company 21 - Needle technology that reveals visible blood flow at the instant of vein penetration without activation or additional instruction
  • Company 22 - Highly accurate, minimally invasive, automatic, and continuous system to measure and monitor cardiac output, total circulating blood volume, and endogenous blood ammonia levels
  • Company 23 - Medical devices and technologies to address the vast liposuction and obesity markets
  • Company 24 - Technology for: 1-prophylactic treatment of allergic asthma and 2-infection control in surgical theatres
  • Company 25 - Non-invasive, controlled, and sustained release back-of-the-eye therapeutics for sight-threatening diseases such as: severe uveitis, diabetic macular edema, and age-related macular degeneration (AMD)
  • Company 26 - Technology that can regenerate nerves
  • Company 27 - Compound that can regenerate new blood vessels and has a biodegradable stent
  • Company 28 - Tissue-engineered, autologous heart valves for the replacement of malformed or malfunctioning heart valves
  • Company 29 - Next-generation robotic surgery system that is: complete, sensitive, flexible, very light, compact, and cost-effective
  • Company 30 - An intraocular lens, customized to the patient\'s vision needs and adjustable throughout the patient\'s life, for greater quality of vision
  • Company 31 - Minimally invasive stents to treat patients suffering from dysfunctional uterine bleeding (DUB), urinary tract obstruction, prostate enlargement (BPH), or prostate cancer
  • Company 32 - 1-Real-time device navigation and positioning system for cardiovascular interventions and 2-Real-time angiography-based system, designed to assist in delivery of a transcatheter heart valve (THV)
  • Company 33 - Biomimetic prosthetic vascular grafts that are transformed in the body into bioartificial arteries which resemble \"healthy\" arteries in form and function
  • Company 34 - Products for restoring blood flow in patients who have suffered acute ischemic strokes
  • Company 35 - Flexible endoscopic tools for interventional gastroenterologists to perform therapeutic procedures
  • Company 36 - Modern, sophisticated system to ensure a proper blood match is obtained and the patient gets the correct cord blood unit in a timely manner
  • Company 37 - Implantable device to treat patients with left ventricular dilation following a Myocardial Infarction (MI) heart attack
  • Company 38 - Blood glucose monitoring system designed to integrate test strips, the lancing device, and lancets into one compact glucose meter
  • Company 39 - A wound dressing constructed from a biocompatible matrix and coagulating agents
  • Company 40 - A handheld, wireless device that detects potential perforations of the vertebral cortex during pedicle preparation for spine surgery
  • Company 41 - Hand-held, battery-powered product using intense therapeutic ultrasound (ITU) technology for skin care
  • Company 42 - Bone cement for cranial defect repair
  • Company 43 - A vascular robotic system designed to place coronary guidewires, stents, and balloon catheters during percutaneous coronary interventions
  • Company 44 - An integrated system featuring sensors and software to enable the monitoring of seniors in multiple care settings
  • Company 45 - Minimally invasive therapy for enlarged prostate
  • Company 46 - Controlled Deployment Technology (CDT), which uses a low-profile access sheath that may be increased to provide a wider working diameter
  • Company 47 - A portable device that provides therapeutic hypothermia in emergency care settings
  • Company 48 - Hand-held, disposable nerve stimulator for use during surgeries
  • Company 49 - An absorbable skin stapler for skin closure that eliminates the need for removing staples after surgery
  • Company 50 - Esophageal cardiac monitoring device for use in surgery and critical care
  • Company 51 - Proprietary devices for obtaining, shaping, and implanting ankle and knee cartilage grafts from foot joints
  • Company 52 - Quantitative and qualitative cardiac assays to assist in the diagnosis of cardiovascular diseases at the point of care
  • Company 53 - Advanced, portable and easy-to-use noninvasive devices for the assessment of traumatic brain injury (TBI) at the point of care
  • Company 54 - Next-generation wellness program with sophisticated physical and mental health diagnostic software
  • Company 55 - Combination of a proprietary ELISA substrate with Raman spectroscopy to dramatically increase the performance of immunoassays for diagnostics, research, and drug discovery
  • Company 56 - Surgical instruments to reduce the trauma of full access surgery
  • Company 57 - Non-ablative skin rejuvenation technology which produces immediate and visible aesthetic improvement together with long-term skin remodeling effects
  • Company 58 - Implantable medical device that helps diabetic patients control their eating habits, lowering their blood glucose and body weight, by applying electrical stimulation to the stomach during meals
  • Company 59 - Ophthalmic devices for minimally invasive treatment of corneal blindness and vision correction using proprietary corneal implants and microsurgical instrumentation
  • Company 60 - Device that measures the presence, progression, and severity of any disease condition and the effectiveness of treatment and timing of non-acute death
  • Company 61 - Non-obtrusive CPAP mask that uses the natural oral cavity anatomy to create the seal required for effective CPAP treatment
  • Company 62 - rEEG(R) technology for the assessment of neurophysiological abnormalities and determination of psychiatric treatment
  • Company 63 - Miniaturized wireless telemetry, physiological monitoring, and rehabilitation devices including applications in electrophysiology, sleep disorders, and movement disorders
  • Company 64 - Dedicated Diabetic Machine (DDM) insulin regulation therapy for type 2 diabetes
  • Company 65 - Non-invasive glucose monitoring device targeting the eye
  • Company 66 - Universal oncology, cardiology, stroke and diabetes molecular imaging agents
  • Company 67 - Fully implantable hearing system (FIHS) placed in the cochlear wall
  • Company 68 - Surgical sponge detection using radiofrequency identification
  • Company 69 - Home monitoring technologies with automatic fall detection capabilities
  • Company 70 - Implantable neuromodulation devices for epilepsy and other neurological disorders
  • Company 71 - Non-invasive cardiovascular monitoring device
  • Company 72 - Single-port, multi-channel laparoscopic surgical platform
  • Company 73 - Advanced over-the-wire vascular access device
  • Company 74 - Technologies that improve visualization during laparoscopic surgery, permit laparoscopic suturing, and enable simpler removal of ureteral stones
  • Company 75 - Portable hyperthermic perfusion system for raising the core temperature of the thoracic or peritoneal cavity
  • Company 76 - Optical guidance systems for computed tomography (CT), fluoroscopy, and magnetic resonance imaging (MRI) procedures
  • Company 77 - Liposome-encased nanoparticles for computed tomography (CT) contrast imaging
  • Company 78 - Cartridge-based portable hemodialysis machine
  • Company 79 - Capillary force vaporizer technology
  • Company 80 - Home-based diagnosis of sleep disorders
  • Company 81 - Office-based, minimally-invasive ablation device for enlarged prostate
  • Company 82 - Medical imaging technologies for clinical and pre-clinical applications
  • Company 83 - Ultrasound systems powered by the Scan Engine, a device that may be interchanged with any of the company\'s 3 carts, promoting efficiency and cost-effectiveness
  • Company 84 - A drug-eluting stent coated with bioabsorbable polymers
  • Company 85 - Parts and services for new and refurbished imaging and patient monitoring technologies
  • Company 86 - Inhalation delivery technologies
  • Company 87 - Synthetic bone substitutes
  • Company 88 - Organ-specific molecular imaging
  • Company 89 - Image analysis for the diagnosis of Alzheimer\'s and other diseases
  • Company 90 - High-speed, disposable dental drill
  • Company 91 - Software systems for cardiology
  • Company 92 - Spinal implant for remote-controlled spine deformity and trauma correction
  • Company 93 - Endoluminal treatment for morbid obesity
  • Company 94 - A non-invasive diagnostic medical device that replaces the current traumatic procedure used to detect pediatric VUR (urinary reflux) and prevent kidney damage in 4M children annually
  • Company 95 - Highly differentiated aorto-ostial stent and delivery platform for both peripheral and coronary applications
  • Company 96 - Medical records application on a simple USB flash drive for patients, providers, and insurers
  • Company 97 - Intelligent orthopedic devices that will address the growing clinical and economic cost of orthopedic implant failure and osteoporosis
  • Company 98 - Occlusion device which provides men seeking a permanent form of contraception with a less-invasive alternative to vasectomy
  • Company 99 - Minimally invasive lumbar annular repair technologies to prevent disc re-herniation and interrupt disc degeneration
  • Company 100 - Web-based service platform, enabled by an imaging technology, for the remote evaluation of skin cancer
  • Company 101 - Device to non-invasively detect and monitor blood borne diseases in vivo, without taking blood
  • Company 102 - Products ranging from needleless injection site connectors, to safety syringes, and biodiagnostic sampling devices
  • Company 103 - Products for the urinary incontinence market
  • Company 104 - New medical diagnostic system for the early detection of lung cancer
  • Company 105 - Non-invasive ultrasound device for the treatment of glaucoma
  • Company 106 - Technology that will impact the way surgeons perform laparoscopic surgery, making it possible for one surgeon to do what now requires two, and to reduce the number of surgical incisions for most all procedures
  • Company 107 - Varicose vein stripping under direct vision for ablation of the diseased saphenous vein in a kit that reduces trauma, minimizes bleeding, and expects improved clinical outcomes
  • Company 108 - Advanced biofeedback stimulator with diagnose and treatment modes
  • Company 109 - Selective cytopheresis-based, modulating system to address inflammation-based diseases and conditions
  • Company 110 - Technology that bridges the gap between low-tech aspiration and complex electromechanical aspiration systems for use in thrombus removal, rotational vacuum assisted biopsy, tissue resection, and spinal disc decompression
  • Company 111 - Medical device for the symptomatic treatment of rhinitis (allergies)
  • Company 112 - Non-compressible hemostatic sealant for high-volume hemorrhage
  • Company 113 - Minimally invasive device for midface lift and other lift procedures
  • Company 114 - Robotic ankle and foot prosthesis
  • Company 115 - Handheld CD4 cell counter
  • Company 116 - Auto-adjusting portable oxygen system
  • Company 117 - Magnetically-guided enteral feeding tube
  • Company 118 - Wireless electrocardiography
  • Company 119 - Human fibrinogen-based tissue sealant
  • Company 120 - Gastrointestinal endoscopy products
  • Company 121 - Interventional cardiology devices for chronic total occlusions
  • Company 122 - Dental imaging
  • Company 123 - Type 1 Diabetes medication delivery
  • Company 124 - Transdermal therapeutics for neurological and psychiatric diseases
  • Company 125 - In-situ formed hydrogels for radiation oncology and oncologic surgery
  • Company 126 - Protein signature-based diagnostic tests for prostate, lung, and breast cancers
  • Company 127 - Synthetic polymer for osteoarthritis therapy
  • Company 128 - Controlled warm air delivery device for human head lice removal
  • Company 129 - Polymolecular system for the treatment of inflammatory disease
  • Company 130 - Critical care monitoring technologies
  • Company 131 - Advanced feeding tube technology which can be placed using ultrathin endoscopes
  • Company 132 - Home healthcare device for use by patients to self-measure Intraocular Pressure (IOP)
  • Company 133 - Ultrasonic technologies and related techniques for aesthetic surgery
  • Company 134 - Therapeutic ultrasound to treat hypertension
  • Company 135 - Breast imaging system for early breast cancer detection
  • Company 136 - RFID technology and software systems for medical device manufacturers, distributors, and hospitals
  • Company 137 - Smart card platform that identifies and authenticates a patient to the healthcare provider and matches the patient to his or her medical record
  • Company 138 - "Lap-Pak" is a flexible, one-piece, device contoured to enable the rapid and secure re-positioning of the bowels to expose the surgical site while eliminating the need for re-positioning during surgery
  • Company 139 - Enhanced meter dose inhalers and spacer devices for the treatment of Asthma and COPD
  • Company 140 - Sensor-based, video-monitored, automatic/semi-automatic laryngoscope that makes intubation easy, safe, and fast
  • Company 141 - Point-of-care automated optical diagnostic device for platelet quality testing
  • Company 142 - Portable diagnostic device used to determine the presence and level of Myocardial Ischemia (MI)
  • Company 143 - Suite of diagnostic imaging products using near-field and forced-resonance principles targeting several specialties including cardiology, oncology, orthopedics, and neurology
  • Company 144 - Rapid endovascular vessel occlusion and blood flow interruption
  • Company 145 - Flat panel x-ray sources for use in sterilization systems, compact CT systems, and a non-radioactive blood irradiator
  • Company 146 - Non-invasive, easy-to-use device that uses pulsed radio frequency energy (PRFE) for tissue growth, wound healing, and pain relief
  • Company 147 - Robotic assistance device for CT-guided soft tissue interventions
  • Company 148 - Fatigue-resistant/fiber-reinforced bone cement for orthopedic joint replacement
  • Company 149 - Full line of products specifically dedicated to avoiding a total joint replacement and preserving the shoulder, hip, knee, or ankle joints
  • Company 150 - Single-use, disposable silver ion delivery device to treat Osteomyelitis (OM)
  • Company 151 - Miniature/high-resolution/low-cost CMOS (complimentary metal-oxide semiconductor) image sensors for use in disposable endoscopic surgical applications
  • Company 152 - Fish-skin-derived tissue regeneration technology for use in a range of reconstructive and orthopedic surgical procedures
  • Company 153 - Hand-held ultrasound device that displays the image in the medical practitioner's line of sight, at the patient's skin surface
  • Company 154 - Minimally invasive ultrasound-guided RF ablation system to treat symptomatic uterine fibroids through a transcervical approach
  • Company 155 - Device that creates a reliable anastomosis to any graft site, for use in CABG and vascular surgeries
  • Company 156 - Rapid/sensitive/cost-effective diagnostic products for detecting microbes causing hospital associated infections
  • Company 157 - Diagnostic products for rapid infection determination at the point-of-care (POC) for professional and consumer markets
  • Company 158 - Cancer immunotherapy device, which selectively removes specific blood-borne inhibitors of the immune system
  • Company 159 - POC/PST device to directly detect clot formation and do it in real time
  • Company 160 - 1-Low-cost, disposable point-of-care (POC) Pap smear replacement requiring no lab or technician; 2-Disposable, woman-controlled, cervical cap embedded with an anti-HIV drug to provide contraception and help prevent infection from HIV
  • Company 161 - Small/wearable/all-mechanical insulin delivery device containing a 3-day supply of insulin
  • Company 162 - Transformative device for detecting and treating breast cancer
  • Company 163 - Stand-alone/rapid/autologous cell harvesting processing and delivery technology
  • Company 164 - System that measures airway inflammation to determine asthma severity for improved treatment
  • Company 165 - Minimally invasive, image-guided therapies to treat back pain
  • Company 166 - Products enhancing focally-delivered radiation and drug therapies for patients with spinal metastatic disease or bone tumors
  • Company 167 - Needle-free drug delivery for migraine attacks and cluster headache episodes
  • Company 168 - Image-guided ultrasound for prostate cancer tissue ablation
  • Company 169 - Obstetric position tracker and ultrasound technology
  • Company 170 - Compact ultrasound devices
  • Company 171 - Continuous blood glucose measurement devices
  • Company 172 - Radiosurgical therapy for neurovascular and inflammatory ocular conditions
  • Company 173 - Wound closure technology
  • Company 174 - Neurosurgical tumor removal
  • Company 175 - Surgical device for treating benign prostatic hyperplasia (BPH) and other conditions
  • Company 176 - Endovascular technology to treat peripheral atherosclerosis in the superficial femoral and popliteal arteries
  • Company 177 - Spine arthroplasty products
  • Company 178 - Implants for sensorineural hearing loss
  • Company 179 - Medical textiles for hemostasis
  • Company 180 - 1-System for use in spinal surgical procedures such as vertebroplasty, 2-System to provide immediate vascular access through the intraosseous space for the delivery of essential drugs and fluids, 3-System for aspirations, biopsies, and stem cell collections
  • Company 181 - Pressure cycling technology (PCT) to safely, conveniently, and reproducibly control the actions of molecules in biological samples
  • Company 182 - Low-cost technology to survey the genome in its native state, in context, and at ultra-high resolution, without the need for DNA amplification
  • Company 183 - Temperature management technology to treat hyperthermia and hypothermia, prevent damage from stroke, and enhance cancer therapies
  • Company 184 - Optical technology for correcting presbyopia
  • Company 185 - Non-invasive radiofrequency (RF) energy-based system to treat vaginal stretching caused by childbirth
  • Company 186 - High-quality, cost-efficient, single-room proton beam radiotherapy (PBRT) system as an alternative to conventional high-energy x-rays
  • Company 187 - Controlled, targeted deep-tissue therapeutic warming system to promote pain relief, reduce joint stiffness, and enhance recovery/rehabilitation programs
  • Company 188 - 1-Artificial larynx, 2-Ear, nose, and throat (ENT) prostheses/implants
  • Company 189 - microRNA-based tests to diagnose various cancers and gastrointestinal diseases
  • Company 190 - Brain training software aimed at enabling individuals to strengthen cognitive function using the concept of neuroplasticity
  • Company 191 - Non-invasive near-infrared (NIR) laser energy for the treatment of: acute ischemic stroke, spinal cord injury, traumatic brain injury, global cerebral ischemia, spinal cord injury, Alzheimer's disease, Parkinson's disease, and sepsis
  • Company 192 - Hydrogel materials that can be fabricated into devices, nanogels, and polymer solutions with applications in ophthalmology as well as cardiology, urology, and tissue engineering
  • Company 193 - Advanced polymer-based biomaterials for applications in cardiology, dentistry, orthopedics, surgery, and urology
  • Company 194 - Neurostimulation device to block residual limb pain caused by complications of amputations, as well as chronic pain after surgery, and migraine pain
  • Company 195 - Joint, spine, and trauma implants
  • Company 196 - "Minimally invasive" gene repair
  • Company 197 - Implantable device for the surgical treatment of obesity without reliance on sutures, staples, or other mechanisms that puncture the stomach wall
  • Company 198 - Microdermabrasion system with polyester/nylon bristle tips and variable vacuum levels for particle-free/crystal-free performance
  • Company 199 - Elastic, self-expanding devices to specifically improve left ventricle relaxation and diastolic function
  • Company 200 - Point-of-care handheld immunoassay system providing high-performance quantitative laboratory blood test results in an inexpensive, portable, and easy-to-use configuration
  • Company 201 - Routine serum DNA blood tests for early cancer diagnosis and management
  • Company 202 - Minimally invasive alternative to the surgical treatment of obesity
  • Company 203 - Drug-eluting balloons that allow for controlled release of different and even multiple substances, for the treatment of coronary (CAD) and peripheral artery disease (PAD)
  • Company 204 - Cancer prognostic tests for predicting specific individual patient clinical outcomes
  • Company 205 - Genomics-based in vitro diagnostic (IVD) tests developed from FFPE tissue for personalized medicine
  • Company 206 - Needleless/transdermal delivery system for insulin, analgesics, or vaccines with on/off control of dosing
  • Company 207 - MRI-compatible ultrasound applicator to deliver controlled thermal therapy to the cancerous regions of the prostate gland
  • Company 208 - Non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system
  • Company 209 - Antimicrobial solutions to reduce the incidence of Surgical Site Infections (SSIs) in spinal surgeries
  • Company 210 - Tissue repair platform that obviates the need for sutures, stapes, glues, or other foreign bodies and instead allows the body to repair and heal itself
  • Company 211 - Catheter-based system to treat large vessel acute ischemic strokes
  • Company 212 - Next-generation remote patient monitoring (RPM) to continuously monitor vital life-sign functions such as: heart rate, respiratory rate, body position, activity level, and skin temperature
  • Company 213 - Total Artificial Heart (TAH) to replace both ventricles of a failed heart, thus, restoring the circulatory system to normalcy
  • Company 214 - Articulating range-of-motion (ROM), non-surgical spinal decompression system to treat herniated, bulged, and injured discs
  • Company 215 - Portable DNA analyzers for on-demand, non-batched testing, with real-time polymerase chain reaction (PCR) results in 30-60 minutes
  • Company 216 - Biomimetic hydrogel implants for spine and other orthopedic applications
  • Company 217 - System designed to prevent contrast-induced nephropathy (CIN)
  • Company 218 - Computer-Aided Diagnosis (CADx) tool for personalized, objective diagnosis and treatment management of musculoskeletal diseases
  • Company 219 - Technology to preserve the normal, healthy tissue of patients that today is damaged as a by-product of current treatments
  • Company 220 - Ventricular Assist Device (VAD) that can be inserted above the diaphragm
  • Company 221 - Handheld, non-invasive, real-time Central Venous Pressure (CVP) monitor for cardiology and nephrology diagnostic applications
  • Company 222 - Next-generation stent platform with: significantly thin walls for reduced restenosis, ease-of-use, superior deliverability, and improved radiopacity for accurate placement
  • Company 223 - In-line, battery-powered, disposable, lightweight, and completely portable blood and IV fluid warming device, capable of intravenous application and irrigation warming
  • Company 224 - Next-generation endovascular devices that incorporate advanced fiber optics technology into currently used products/procedures to improve patient outcomes without adding to procedure time/cost
  • Company 225 - Digital fluorescence scanners for molecular pathology research, biomarker development, and clinical molecular diagnostics (MDx) for personalized medicine
  • Company 226 - Technology to enable home healthcare providers to provide better patient care while improving operational efficiency by 20-30%
  • Company 227 - Polymer technologies for drug delivery and regenerative medicine with applications in orthopedics and spine
  • Company 228 - A-FX(TM) is a minimally invasive platform technology for creating an orthopedic implant in-situ which provides superior fixation in osteoporotic bone
  • Company 229 - Non-invasive device designed to offer transcutaneous pulsed electro-magnetic field stimulation therapy for treating postoperative pain and edema in superficial soft tissue
  • Company 230 - Non-invasive reverse thermal gradient technology to treat conditions of tendons, ligaments, muscles, fasciae, and joints
  • Company 231 - Automatic screw delivery system for cranial maxillo-facial bone fasteners
  • Company 232 - Non-invasive brain physiological measurement technologies
  • Company 233 - Smallest/passive/implantable tag using RFID (radio-frequency identification) technology
  • Company 234 - Diabetic pain relief via topical dermal administration and controlled release of pure Nitric Oxide (NO)
  • Company 235 - Set of catheters for percutaneous isolation of an organ and local delivery of any high-dosage chemotherapy for treatment of organ cancer
  • Company 236 - Vacuum-based clean surface nanotechnology for faster and larger osseointegration
  • Company 237 - Technology for: 1-Glaucoma diagnosis and 2-Real-time homecare monitoring of intraocular pressure (IOP)
  • Company 238 - Precision stapling devices enabling minimally invasive vascular connections, especially for Coronary Artery Bypass Graft (CABG) surgery
  • Company 239 - Therapeutic substances for bone regeneration
  • Company 240 - Functionalized injectable biopolymers for medical applications
  • Company 241 - Mobile air purification unit that captures and destroys airborne pathogens
  • Company 242 - Therapy delivery platform for the upper airway with applications to initially target chronic sinusitis, nasal allergies, cystic fibrosis, and CPAP users
  • Company 243 - 1-Multi-generational devices using hybrid technologies for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures, 2-Low profile single-patient-use tissue retractor, 3-Range of 7Fr intra aortic balloon catheters with fluid-filled technology that plugs into current hardware
  • Company 244 - Percutaneous anastomosis device for vascular access
  • Company 245 - Intelligent 3DHD visualization and guidance platform for ophthalmic, cranial, and spine surgeries
  • Company 246 - Wireless/battery-less antenna on a chip (tag) for continuous tracking of blood samples
  • Company 247 - Permanently implanted electrical neural stimulators to treat balance/hearing/perceptual disorders
  • Company 248 - Real-time advanced fluid sensing with smart solutions for safe preparation and delivery of IV medications
  • Company 249 - Electrical stimulators via electrode garments for the treatment of pain related to chronic/acute soft tissue injuries
  • Company 250 - Non-invasive neuromodulation platform technology
  • Company 251 - Surgical instrument designed to solve recurrent problems in managing sutures, tissue reattachment, and visualization during surgical procedures
  • Company 252 - Nanolayer surface technology to improve the osteoconductive/bio-resistant/anti-infective attributes of implants
  • Company 253 - 1-Biopsy needles with enhanced ultrasound visualization, 2-Microencapsulated tissue markers, 3-Devices for the local, accurately positioned chemoablative treatment of soft tissue cancers
  • Company 254 - Accommodative intra-ocular lens (IOL) technology to treat cataracts/presbyopia/impaired vision
  • Company 255 - Systems to diagnose neurological and sleep disorders
  • Company 256 - Technology that precisely eliminates irregularly shaped/invasive solid tumors while avoiding significant damage to surrounding healthy tissue and is non-toxic
  • Company 257 - Extracellular matrix (ECM) implant that is completely integrated, remodeled, and replaced by the patient’s native tissue over time
  • Company 258 - Non-surgical/injectable tissue revitalization and stabilization to address lower back pain (LBP) and the underlying problem of mechanical insufficiency
  • Company 259 - 1-System for remote home patient monitoring of glucose, blood pressure, and thermal weight, 2-Glucose meter cell phone
  • Company 260 - Non-invasive ophthalmic medical devices for: 1-diabetes screening and 2-daily glucose monitoring
  • Company 261 - Implantable replacement valve to treat incompetent deep vein valves causing degenerative pain, swelling, and non-healing ulcers associated with chronic venous insufficiency (CVI)
  • Company 262 - Advanced blood purification to reduce cytokine storm and inflammation that leads to multi-organ failure in sepsis and other critical care diseases
  • Company 263 - Next-generation anatomic pathology (AP) with improved speed, automation, and ease-of-use
  • Company 264 - Injectable biopolymer for the direct treatment of acute myocardial infarction (AMI)
  • Company 265 - Invisible/battery-less hearing device that is permanently implanted, yet completely reversible and MRI-compatible/safe
  • Company 266 - Wireless device for the treatment of stress/urge/mixed urinary incontinence (UI)
  • Company 267 - Communication device that acquires neurological signals from the brain and translates them into speech
  • Company 268 - Visually guided catheter ablation for atrial fibrillation
  • Company 269 - Next-generation vessel closure
  • Company 270 - Pneumatic compression devices targeted to the lymphedema, venous insufficiency, and sports medicine markets
  • Company 271 - Technology that enables the "packaging" of chronic therapies/biologics in an easy-to-use, disposable patch-like device
  • Company 272 - Instrumentation that provides surgeons with real-time sensing/feedback from the operative site
  • Company 273 - Lab-free salt intake monitor for hypertension/congestive heart failure (CHF) patients
  • Company 274 - Endoscopically placed device for the treatment of obesity
  • Company 275 - Minimally invasive radiofrequency (RF) device to treat aging skin
  • Company 276 - Optical biopsy needle that will accurately diagnose prostate cancer, yet eliminate random prostate biopsies
  • Company 277 - New holding company for various orthopaedic device companies, such as Enztec and OMNI life science
  • Company 278 - Catheters for dissolving/removing cerebral blood clots then delivering therapeutics to the diseased site
  • Company 279 - Targeted molecular assays for onco-diagnostics/personalized medicine
  • Company 280 - Biomarker discovery platform for detecting Type 2 Diabetes, Prostate Cancer, and Amyotrophic Lateral Sclerosis (ALS, aka Lou Gehrig's disease)
  • Company 281 - Molecular diagnostic technologies for organ transplantation and various complex genetic disorders
  • Company 282 - Non-invasive breast cancer diagnostic test via breast fluid analysis
  • Company 283 - Non-invasive vascular disease detection that combines the advantages of MRI with the temporal resolution and ease-of-use of ultrasound
  • Company 284 - Endoscopic/removable device that mimics the effects of gastric bypass surgery on a patient's metabolism
  • Company 285 - "Smart" cells than can determine the type of disease/injury present in the body and repair/regenerate tissue accordingly
  • Company 286 - Imaging systems for the non-invasive, in vivo detection of cancerous and pre-cancerous lesions
  • Company 287 - Microarray-based technology enabling targeted next-generation sequencing of genomic regions of interest
  • Company 288 - Minimally invasive therapy for Emphysema
  • Company 289 - Comfortable, soft, and pliable cloth mask for the treatment of obstructive sleep apnea
  • Company 290 - Wearable neuroimaging cap for mapping brain function
  • Company 291 - Computer-controlled rehabilitation table for the management of lower back pain
  • Company 292 - 1-Bioactive/conductive polymer materials and coatings for implantable biomedical devices and 2-Next-generation all-polymer leads that may be grown in the body
  • Company 293 - Non-invasive diagnostic prenatal testing via maternal blood test
  • Company 294 - Devices to treat low back pain
  • Company 295 - Wearable sensor technology that safely and accurately measures individual sleep patterns
  • Company 296 - Vascular navigation system designed to more accurately and rapidly position venous catheters (CVC and PICC)
  • Company 297 - Minimally invasive breast tumor diagnosis and treatment
  • Company 298 - Lightweight, waterproof, medical alert pendant for seniors - to avoid the dangers of missed medications
  • Company 299 - Non-invasive DNA-based prenatal diagnostic test
  • Company 300 - Heart pump technologies
  • Company 301 - DNA sequencing technology for the detection of biomarkers for infectious and other diseases
  • Company 302 - Computer-assisted surgical devices for total joint replacement
  • Company 303 - Diagnostic and therapeutic ophthalmic devices
  • Company 304 - Nanomaterials for angiogenesis/anti-angiogenesis/diagnostic applications
  • Company 305 - Non-invasive neurostimulation device to restore vision to patients suffering from stroke, traumatic brain injury (TBI), dry age-related macular degeneration (AMD), and glaucoma
  • Company 306 - Surgical/restorative dental implants
  • Company 307 - Molecular diagnostic/prognostic tests for cancer
  • Company 308 - Device to treat osteoarthritis
  • Company 309 - Minimally invasive implant for treating spinal stenosis
  • Company 310 - Non-polymeric drug-eluting stent (DES)
  • Company 311 - Variety of diagnostic tests for infectious diseases, cardiology, hepatology, and various cancers
  • Company 312 - Non-woven fabric with extended shelf-life to restore/repair tissue function
  • Company 313 - Device for removing uterine fibroids without hysterectomy
  • Company 314 - Wearable display technology to restore quality of life for those suffering from age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and retinitis pigmentosa (RP)
  • Company 315 - Diagnostic retinal imaging system for use in the primary care setting
  • Company 316 - Easy-to-use/automated/rapid detection of severe infectious diseases
  • Company 317 - Inferior vena cava (IVC) filter that includes: 1-automatic self-centering, 2-bi-directional deployment and retrieval, 3 -atraumatic design, and 4-total transluminal filtration
  • Company 318 - Compliant balloon platform technology for use in neuroradiology, cardiovascular, and peripheral vascular applications
  • Company 319 - Mechanical thrombectomy device to treat ischemic stroke
  • Company 320 - Artificial heart technologies
  • Company 321 - Cancer diagnostic test which enables the development of personalized therapeutics
  • Company 322 - Bone graft material that is: 1- synthetic, 2-non-immunogenic, 3-inclusive of all bone regenerative properties of an autograft, and 4-cost-effective
  • Company 323 - Portable/rapid cooling technologies via the nasal cavity to improve patient outcomes after cardiac arrest, stroke, or traumatic brain injury (TBI)
  • Company 324 - Tests for the diagnosis/prognosis of cardiovascular disease
  • Company 325 - Cost-effective solutions for the improved detection and prevention of cancer in the gastrointestinal (GI) tract
  • Company 326 - Neuromodulation for hypertension/heart failure
  • Company 327 - System to repair abdominal aortic aneurysms (AAA)
  • Company 328 - Endoscopic device to treat sinusitis
  • Company 329 - Allogeneic cell therapy derived from the human placenta to mimic the natural environment of bone marrow
  • Company 330 - Aortic embolic protection device for acute and long-term use
  • Company 331 - Autologous adult stem cell technology, cultured from the nasal passageway, to repair damage resulting from spinal cord injury
  • Company 332 - 1-Minimally invasive treatment of spinal compression, 2-Minimally invasive treatment of long bone factures, 3-Neuromodulation catheter that can be introduced into the spinal canal to treat pain
  • Company 333 - Next-generation needleless drug delivery
  • Company 334 - Minimally invasive neurosurgical and orthopedic instruments and implants
  • Company 335 - Tissue fusion via infrared laser to replace sutures
  • Company 336 - Ultrasound system that can measure true tissue elasticity in a reproducible/quantifiable/user-independent manner
  • Company 337 - Next-generation nanostructured capacitors for: 1-implantable cardiac defibrillators (ICD) and 2-microsteerable cardiac ablation and related catheters
  • Company 338 - Minimally invasive spine implant (facet versus pedicle screw)
  • Company 339 - Spine implant that allows for post-operative adjustment of the implant size via radio control
  • Company 340 - Spine fusion implant for motion preservation/dynamic stabilization
  • Company 341 - Next-generation "permanent" biomaterial to reduce the risk of infection/thrombosis/restenosis
  • Company 342 - Device for the treatment of benign prostate hypertrophy (BPH), prostatitis, erectile dysfunction (ED), lower urinary tract symptoms, and infertility
  • Company 343 - Andara technology for the treatment of acute spinal cord injury
  • Company 344 - Polymer implant to repair meniscal tears via tissue regeneration
  • Company 345 - Electrodes/neural interface products for functional neurosurgery and neurostimulation
  • Company 346 - Non-systemic/non-invasive system that delivers magnetic versus electrical pulses for the treatment of depression
  • Company 347 - Implantable neuromodulation device designed to electrically alter the pain signal pathways
  • Company 348 - Next-generation implants, stem cell enabling technology, and other minimally invasive surgical instruments
  • Company 349 - Invisible hearing device
  • Company 350 - Cooling and compression therapy for the relief of pain/swelling after orthopedic/other surgery
  • Company 351 - Catheter insertion systems, designed for extended IV dwell time, to eliminate the risk of related bloodstream infections
  • Company 352 - A monthly, rapid test to accurately monitor and potentially diagnose Diabetes
  • Company 353 - Products for coronary bypass, valve repair and replacement, cardiac ablation, and heart failure surgery
  • Company 354 - Biomaterial with exceptional hardness/low friction/bio-inertness that also prevents the leaching of metallic ions into the body
  • Company 355 - Disposable and needleless patch that can be placed on the body inconspicuously for insulin delivery - an alternative to daily insulin injections
  • Company 356 - Small shunt-like device implanted into the bloodstream to modify, collect, or eliminate a broad range of Target Cells
  • Company 357 - Artificial heart made of biosynthetic tissues, with two-pumps
  • Company 358 - Permanently implantable/wireless/miniature sensors to transmit cardiac output, blood pressure, and heart rate data
  • Company 359 - Fully implantable device for the treatment of central sleep apnea in heart failure patients
  • Company 360 - Heart valve implant
  • Company 361 - Tool for early diagnosis of age-related macular degeneration (AMD)
  • Company 362 - Nanotechnology-based liquid that absorbs energy on a near-molecular scale versus relying on the mechanical properties of solid materials
  • Company 363 - Cyanoacrylate-based products for wound care and infection prevention
  • Company 364 - Femtosecond pulse laser system for various ophthalmic applications
  • Company 365 - Technology that uses the patient\'s own blood to make either: 1-A surgical sealant to prevent/stop bleedings or 2-A gel to stimulate the healing of chronic wounds
  • Company 366 - Real-time/multi-user image communication/collaboration system that consolidates images and text records into a single point of access
  • Company 367 - Polymer-based/biodegradable/drug-eluting peripheral vascular stent for tibial and infrapopliteal arteries
  • Company 368 - Ultrasound-based diagnostic biosensor that enables blood analysis at the molecular level for the patient self-testing market
  • Company 369 - Non-invasive biomechanical diagnostic system that records/analyzes range of motion (ROM) in a full 3-D environment for musculoskeletal diagnostics/therapeutics
  • Company 370 - Minimally invasive/endoscopically-placed device to treat obesity by inducing satiety in the esophageal/cardiac portion of the stomach
  • Company 371 - Continuous glucose monitoring specifically for use in the Intensive Care Unit (ICU)
  • Company 372 - Real-time interactive training visualization system, specifically for the task of training any designated personnel in successfully accomplishing a limited "focused assessment with sonography for trauma" (FAST) examination
  • Company 373 - Molecular diagnostic tests to: 1-Differentiate between squamous and non-squamous non-small-cell lung cancer, 2-Differentiate between mesothelioma and adenocarcinoma, 3-Identify more than 20 types of cancer
  • Company 374 - Nasal stent to treat obstructive sleep apnea
  • Company 375 - 1-Pacing/sensor-enabled device for Cardiac Resynchronization Therapy (CRT), 2-Real-time modality to quantify cardiac performance, 3-System that adds ingestible microchips to drugs
  • Company 376 - Pocket-sized, affordable, and easy-to-use resuscitation devices that can be effectively deployed by both trained professionals and laymen
  • Company 377 - Wearable health monitoring system for potential diabetes, heart disease, and sleep apnea applications
  • Company 378 - Biomarkers for the screening and diagnosis of cervical and other cancers
  • Company 379 - Wireless neurostimulation device to treat refractory chronic pain - 100 times smaller than current technology and injectable via a minimally invasive hypodermic needle
  • Company 380 - Smart, accurate guiding device based on image technology for orthopedic trauma procedures such internal fixation with intramedullary (IM) nails, osteotomy, and others
  • Company 381 - Non-invasive molecular diagnostics for autism, chronic obstructive pulmonary disease (COPD), multiple sclerosis, and diseases with a genetic susceptibility
  • Company 382 - Natural polymer technology that mimics the physiological clotting cascade without reliance on blood-derived proteins - to stop severe bleeding, reinforce staple and suture lines, and repair tissues
  • Company 383 - Effective and convenient phototherapy system available for in-home treatment of scalp/small-area psoriasis and other photo-responsive skin diseases
  • Company 384 - Electroporation-delivered/DNA-based vaccines against cancers and infectious diseases
  • Company 385 - Next-generation computer-assisted laparoscopic tool composed of multiple rigid elements with intervening controllable joints
  • Company 386 - Low-cost/point-of-care (POC) analyzer to quantify hemostasis in whole blood, including cellular and plasma components
  • Company 387 - Fluorescent markers/optical sensors that provide an accurate and rapid determination of kidney function
  • Company 388 - Ocular scanner for rapid/non-invasive triage and detection of pre-symptomatic conditions including exposure to toxins, presence of systemic diseases, and indication of internal injury
  • Company 389 - Endoscopically implantable devices for weight loss/to control Type 2 diabetes
  • Company 390 - Catheter ablation for the treatment of cardiac arrhythmias
  • Company 391 - Monitoring products/clinical services for advanced ambulatory cardiac monitoring
  • Company 392 - Technology used in: 1-Finished products designed for micro-surgical/microscopy procedures and robotics and 2-Biosensors with applications in gene expression, neuroscience, and nanotechnology
  • Company 393 - Resorbable hydrogel that 1-Seals annular tears in the intervertebral disc and 2-Provides an environment for nucleus regeneration
  • Company 394 - Non-invasive/fast/easy-to-use/reliable medical devices that test for neuro-visual disorders
  • Company 395 - High-dose drug delivery system for the minimally invasive and repeatable treatment of liver cancers, colorectal cancer, and hepatitis
  • Company 396 - Technologies that integrate bone and cartilage forming peptide and small molecule therapies with osteostimulating matrices
  • Company 397 - Non-invasive devices to identify patients with coronary artery disease (CAD) and other life-threatening cardiovascular conditions
  • Company 398 - Injectable porous scaffolds/spheres/composites with fully interconnected pores, for multiple applications
  • Company 399 - Compact, remote, wireless, real-time device for biomedical monitoring such as cardiac, neurological, sleep disorder, obstetrics, orthopedic, and other vital signs outside the hospital/clinic
  • Company 400 - Permanent implant to address mitral regurgitation directly
  • Company 401 - Portable/lab-quality diagnostics for the ER/ambulance/physician's office/home/field
  • Company 402 - Percutaneous injection treatment for patients with internal disc derangement (IDD) who have failed conservative care/are not yet candidates for total disc replacement (TDR)/spinal fusion
  • Company 403 - Technology that allows surgeons to rapidly treat tissue at the surgical site/reduce blood loss
  • Company 404 - A1c diabetes testing at the point of care, with results in under 4 minutes
  • Company 405 - Next- generation/predictive blood tests to help warn of potential future health problems
  • Company 406 - Vertebral compression fracture treatment
  • Company 407 - Orthopedic imaging
  • Company 408 - 1-Artificial vascular graft with self-sealing, non-woven, synthetic fiber structure, 2-Ventral hernia mesh
  • Company 409 - 1-Prohealing coronary stent as an alternative to drug-eluting stents (DES), 2-Balloon -expandable/crush-resistant nitinol peripheral stent, 3-Nano-based transcatheter, 4-Anatomy-specific combination embolic protection and stent delivery systems, 5-Localiz
  • Company 410 - Early detection of Alzheimer's disease via an eye drop and laser eye scan
  • Company 411 - Drug-coated balloon angioplasty technology
  • Company 412 - Behavioral remote patient monitoring system that uses wireless sensors to non-intrusively track and report on the daily patterns of seniors' activities
  • Company 413 - System that assesses, then provides therapy to develop infant feeding skills
  • Company 414 - Painless, continuous glucose monitoring
  • Company 415 - Wireless/wearable/ultra-compact device that automatically tracks/wirelessly uploads data about a person's activities (exercise intensity levels, calories burned, sleep quality, steps, distance)
  • Company 416 - Joint reconstruction device that ideally/anatomically matches the size/shape of the facet joint
  • Company 417 - Platforms for: 1- Pedicle screw fixation (even with poor bone quality), 2-Vertebral compression fractures, 3-Simple- to-use trauma products
  • Company 418 - Implantable device for maintaining adequate blood flow to the brain in patients experiencing a buildup of excess cerebral spinal fluid (CSF) due to trauma
  • Company 419 - 1- Straightforward knotless suture anchor, 2-Instrumentation for percutaneous suture management, 3- Endotendonous repair system, 4-Shape memory staples
  • Company 420 - Coagulation analyzer to eliminate unnecessary blood transfusions
  • Company 421 - Simple, rapid, blood-based cancer tests to provide accurate and individualized clinical information on disease status/treatment selection/treatment response
  • Company 422 - Neurostimulator for cardiac contractility
  • Company 423 - Endoscopically delivered devices focused on slowing gastric emptying, to treat all stages of obesity
  • Company 424 - Autonomic nervous system stimulation for pulmonary and headache disorders
  • Company 425 - Optimization of T cell receptors (TCRs) for use in adoptive T cell therapy - to target and destroy cancerous/infected cells
  • Company 426 - Technology for wound care and slow release drug delivery, by both transdermal and subcutaneous routes
  • Company 427 - Intraoperative wavefront aberrometer for use in intraocular lens replacement surgeries
  • Company 428 - Technology to treat atrial fibrillation that allows doctors to perform radiofrequency ablation under direct visualization
  • Company 429 - Tests to "predict" chronic diseases/conditions, such as diabetes/osteoporotic bone fracture/a major cardiac event
  • Company 430 - Disposable/miniature/minimally invasive surgical devices including reusable endoscopes for visualization, initially for use in spinal surgeries
  • Company 431 - Dental implant that can be placed into a multi-rooted molar extraction site "immediately"
  • Company 432 - Biocompatible and biodegradable synthetic scaffold to aid soft tissue regeneration of the anterior cruciate ligament (ACL) of the knee
  • Company 433 - Ingestible/wireless capsule with sensor technology to measure pH, pressure and temperature from within the entire GI tract
  • Company 434 - Counter-stimulation technology to treat Restless Legs Syndrome (RLS)
  • Company 435 - Minimally invasive device to treat emphysema
  • Company 436 - Gene expression test for the diagnosis of ambiguous tumors
  • Company 437 - Ocular metabolic imaging to "predict" eye diseases, including diabetic retinopathy/glaucoma/age-related macular degeneration
  • Company 438 - Implantable neuromodulation device for the treatment of chronic pain and future applications
  • Company 439 - Home-use devices for hair removal/acne/skin rejuvenation
  • Company 440 - Technology that restores natural physiologic outflow as a foundation of significant/steady/sustained glaucoma management
  • Company 441 - Minimally invasive surgery system for simpler and safer soft-tissue suturing/fastening
  • Company 442 - Effective/consistent/non-invasive neuromodulation for the treatment of urinary incontinence and future applications
  • Company 443 - 1-Needleless mesotherapy to treat cellulite, 2-Non-invasive/non-thermal treatment for skin laxity/hypertrophic scars/striae
  • Company 444 - Laparoscopic instruments that articulate/rotate/lock for single port access/"scar-less" surgery
  • Company 445 - Miniature implantable sensors to accurately/continuously pinpoint the location of tumors in real-time, during radiation therapy delivery
  • Company 446 - Manual rongeur and access tools for use in spinal decompression procedures
  • Company 447 - Convenient/improved continuous glucose monitoring system
  • Company 448 - Coating that triggers the body to generate nitric oxide (NO) at the device surface, by using naturally circulating blood substances
  • Company 449 - Real-time/in vivo/cellular-level/3-D imaging for: image-guided surgery; early cancer diagnosis without a biopsy
  • Company 450 - In vivo transdifferentiation to regenerate ischemic/diseased organs
  • Company 451 - Oxygen metabolic imaging bioscale (TVI-agents) which are injected intravenously prior to imaging in a standard MRI scanner
  • Company 452 - True seizure "prediction" - up to an hour before the event
  • Company 453 - Wearable mobile device to accurately measure real-time energy (calorie) expenditure/combat obesity
  • Company 454 - 1-Non-embryonic cell technology that creates cells/tissues/organs for virtually anyone needing a transplant, 2-Non-toxic cancer vaccine that uses the body's natural immune response to fight cancer, 3-Cell separation system to diagnose/monitor cancer
  • Company 455 - Custom miniaturized mechanical components/devices for a broad range of medical device applications
  • Company 456 - Wireless/disposable sleep-monitoring device
  • Company 457 - 1-Next-generation, natural fibrin sealant, 2-Human thrombin
  • Company 458 - Affordable, simple-to-use means of self-monitoring women's reproductive status for: conception, birth control, ovulation, and cervical cancer screening
  • Company 459 - Technologies that focus on wound diagnostics, infection control, and wound therapy
  • Company 460 - Wireless/MEMS-fabricated/nano-processed/dermal/percutaneous continuous glucose monitoring device
  • Company 461 - Diagnostic instrument to measure the material properties of bone
  • Company 462 - Electronic Brachytherapy (eBx) systems based upon miniaturized x-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments
  • Company 463 - Minimally invasive method for lumbar spine decompression to treat patients with lumbar spinal stenosis (LSS), which may be performed in conventional operating rooms or interventional radiology suites with fluoroscopic imaging
  • Company 464 - Next-generation respiratory device that delivers synchronization of flow/temperature/humidity/oxygen percentage, without discomfort, via nasal cannula
  • Company 465 - Minimally invasive system to treat emphysema and resolve prolonged air leaks following lung surgery
  • Company 466 - 3-D mesh pouches that are implanted empty, positioned, filled, then deployed to their full size for spinal/orthopedic applications
  • Company 467 - Painless photo-pulsation technology for diminishing fine lines/wrinkles/age spots on the face/neck/hands
  • Company 468 - Plastic surgery implantable devices for cosmetic and reconstructive surgery
  • Company 469 - 1-Soft/disposable contact lens with embedded MEMS sensor for continuous intraocular pressure (IOP) monitoring in glaucoma patients, 2-Telemetry solutions for implantable medical devices
  • Company 470 - Technology for the non-fusion treatment of scoliosis
  • Company 471 - Atraumatic injectable plugs for 1-Temporary occlusion of blood vessels, 2-Kidney stone removal, and 3-future applications
  • Company 472 - Percutaneously deliverable endograft to treat Abdominal Aortic Aneurysms (AAA) and Thoracic Aortic Aneurysms (TAA)
  • Company 473 - Optical Coherence Tomography (OCT) for sub-surface biological tissue imaging at much greater resolution than ultrasound/MRI/CT scanners
  • Company 474 - Next-generation femtosecond laser that can operate inside the eye to make cataract surgery safer/more effective
  • Company 475 - Totally implantable pumps delivering targeted medications directly to the spinal cord
  • Company 476 - Rapid, point-of-care diagnostic tests for periodontitis/group A strep/systemic fungal infections, capable of detecting virulence markers produced ONLY during active infections
  • Company 477 - Therapeutic gene delivery
  • Company 478 - 1-Vertebral augmentation system and 2-On-demand ultra-high viscosity cement injection, for spinal applications
  • Company 479 - Miniature implantable neurostimulator for treating central nervous system disorders
  • Company 480 - Simple, point-of-care blood test for the detection/monitoring of traumatic brain injury (TBI)
  • Company 481 - Resurfacing system to treat lesions/defects in the body's weight bearing, non-weight bearing, and extremity joints
  • Company 482 - Molecular imaging of apoptosis (programmed cell death) for disease detection/monitoring
  • Company 483 - Technology to close incisions made during Natural Orifice Transluminal Endoscopic Surgery (NOTES) procedures
  • Company 484 - Transitional in vivo imaging
  • Company 485 - Collapsible titanium-alloy implant for spinal fusion
  • Company 486 - Non-invasive type 2 diabetes and pre-diabetes screening with no blood draw/no fasting/no waiting for a lab result
  • Company 487 - Devices for the destruction of pathogens responsible for: heart/blood/respiratory/gastrointestinal/periodontal/otological diseases, pancreatic cancer, and toe nail fungus
  • Company 488 - Device that delivers a low-level/precisely controlled heat for the treatment of acne
  • Company 489 - Nanomaterial-based MRI coil for higher image quality/faster scan times
  • Company 490 - Handheld/at-home hair removal via laser
  • Company 491 - Enhanced diabetes insulin pump
  • Company 492 - Transpedicular/minimally invasive approach to vertebral body reconstruction/anterior spinal column support
  • Company 493 - Next-generation Spinal Cord Stimulation (SCS) technology to treat chronic back/lower extremity pain
  • Company 494 - Dynamic/intelligent ophthalmic lenses that automatically/electronically adjust focusing power
  • Company 495 - Blood screening tests for breast and ovarian cancers
  • Company 496 - Implantable/battery-less diagnostic system to allow orthopedic surgeons to monitor spinal fusion progress
  • Company 497 - Next-generation coatings/advanced drug-delivery systems for cardiovascular stents and other implantable medical devices
  • Company 498 - Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) device for acute coronary syndrome (ACS) and heart failure patients
  • Company 499 - Ultra-thin/personalized/single-use/flexible/transdermal drug delivery patch
  • Company 500 - DNA-based diagnostic tests for early identification/management of cancer/acute diseases
  • Company 501 - Device with bio-active formulae to rapidly/painlessly treat/control the wound environment
  • Company 502 - Less invasive treatment for chronic sinusitis delivered via non-nasal access
  • Company 503 - Leadless/implantable pacing device for left ventricular stimulation/the treatment of heart failure
  • Company 504 - Technologies to acquire/process/visualize data from 3-D breast imaging
  • Company 505 - Mental stimulation system to help maintain mental acuity/quality of life
  • Company 506 - Implantable device to treat high blood pressure that cannot be controlled with medications/lifestyle modifications
  • Company 507 - Polymer technologies for cardiac/cranio-maxillofacial/orthopedic surgery applications
  • Company 508 - Leadless/subcutaneously implantable cardiac defibrillator (ICD)
  • Company 509 - 1-Handheld intelligent bone sculpting tool, 2-X-ray vision that appears "within" the patient
  • Company 510 - Synthetic peptides for tissue regeneration for the treatment of musculoskeletal/vascular/chronic wound diseases
  • Company 511 - Radiofrequency (RF) energy to reshape the cornea without incision
  • Company 512 - Endovascular treatment of peripheral arterial blood vessels that require re-vascularization
  • Company 513 - Cells derived from bone marrow which can be used in an allogeneic/off-the-shelf setting to treat kidney/other difficult to treat diseases
  • Company 514 - Thin-walled/removable/entirely covered stents designed to match the site to be treated and the surrounding anatomy
  • Company 515 - Technologies to: 1-Treat the progression of age-related macular degeneration (AMD) and retinitis pigmentosa (RP), 2-Stop/reverse some of the vision loss from Glaucoma, 3-Prevent diabetic retinopathy, 4-Greatly enhance pars plana vitrectomy surgery
  • Company 516 - Single device for high-frequency ultrasound imaging/therapeutic treatment
  • Company 517 - Low-level laser technology for aesthetics, bone healing, neck/shoulder pain, and wound healing
  • Company 518 - Light-based aesthetic systems that are pain-free/seven times faster than existing systems
  • Company 519 - 1-Image analysis technology for virus detection/analysis, 2-Antiviral drugs
  • Company 520 - Simultaneous testing of sobriety and identy that is simple/rapid/non-invasive, requiring no bodily fluids
  • Company 521 - Technology for diagnosing breast and ovarian cancers and determining responsiveness to new therapeutics
  • Company 522 - Synthetic graft/stent technology that reduces neo-intimal hyperplasia (NIH) and occurrence/rate of restenosis
  • Company 523 - Disposable endoscopic assist device that can be used with existing equipment to significantly improve flexible endoscopy procedures
  • Company 524 - Systems using radiofrequency (RF) energy for the treatment of GERD and fecal incontinence (FI)
  • Company 525 - Sutureless anastomosis systems to reduce/eliminate cross clamping time and suturing during minimally invasive surgery (MIS)
  • Company 526 - Anti-infective compounds designed to mimic host defense proteins, but with completely synthetic/non-peptide backbones
  • Company 527 - Minimally invasive interstitial laser therapy (ILT) as an alternative to breast surgery
  • Company 528 - Less invasive approach for mitral valve repair, on a beating heart
  • Company 529 - High-resolution dermoscopy imaging technology to identify melanoma at an earlier stage/reduce the number of unnecessary excisions
  • Company 530 - Nanotechnology surface treatments for combination medical devices that address nosocomial (in-hospital) infections and thrombus
  • Company 531 - Non-invasive, fully automated system for the accurate assessment of : cardiovascular/diabetic autonomic neuropathy, effectiveness of beta-blocker therapy, and risk stratification of sudden cardiac death
  • Company 532 - Wireless/motorized orthopedic lengthening implants for applications in deformity correction/cosmetic limb lengthening/bone fractures
  • Company 533 - 3-D scaffold that enhances the biointegration of percutaneous/fully implanted current and next-generation devices
  • Company 534 - Injectable gels for localized and controlled release of biologicals
  • Company 535 - Portable/palm-held endoscopic imaging with a mobile platform for recording/sharing/archiving images
  • Company 536 - Hand-held ultrasound device to quantify strain and stiffness of tendons/ligaments
  • Company 537 - Lightweight brace support suit that restores mobility function for paraplegics/lower limb paralysis patients
  • Company 538 - Non-invasive gene expression-based tests for the monitoring of transplant rejection/autoimmune diseases
  • Company 539 - Cobalt-chromium, balloon-expandable stent, which marries with approved DES to treat the entire spectrum of coronary artery bifurcation lesions
  • Company 540 - Non-invasive intracranial pressure monitor to diagnose/treat head injury
  • Company 541 - Temperature-controlled/multi-functional next-generation cutting/sealing product
  • Company 542 - Interspinous/interlaminar functionally dynamic stabilization device and other non-fusion scoliosis technologies
  • Company 543 - CO2 lasers through flexible/rigid endoscopes for use in minimally invasive surgery and soft tissue procedures in otolaryngology/head and neck surgery/pulmonology
  • Company 544 - Real-time/PCR-based molecular diagnostic tests for life-threatening respiratory fungal infections
  • Company 545 - Ultra-lightweight/soft/non-palpable mesh technology to treat urinary stress incontinence/pelvic organ prolapse
  • Company 546 - Digital pump with no mechanical parts for drug delivery/infusion therapies
  • Company 547 - Surgical implants and biological products for spinal surgery
  • Company 548 - In situ formed hydrogels designed/indicated for ophthalmic surgery
  • Company 549 - Light-activated glue system to stabilize shattered bone
  • Company 550 - Non-contact imaging system that provides local anatomical and oxygenation information
  • Company 551 - Affordable/good quality standard-of-care surgical devices
  • Company 552 - Low-dose-rate brachytherapy that will replace individual seeds and provide more uniform/consistent radiation delivery to patients
  • Company 553 - Recombinant adeno-associated viral (AAV)-based gene therapy as a treatment for congestive heart failure (CHF)
  • Company 554 - Aortic valve bypass graft system for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy
  • Company 555 - Single-use catheter device w/controller that delivers radiofrequency energy during outpatient bronchial thermoplasty for the treatment of asthma
  • Company 556 - Ultrasonic energy for the selective dissection/fragmentation/debridement/cleansing of tissues
  • Company 557 - Percutaneous soft tissue lifts for the breast/neck/other soft tissue structures
  • Company 558 - Bioresorbable polymer surgical implants designed to prevent/reduce the formation of post-operative adhesions
  • Company 559 - Implanted electronic subretinal device to restore vision to those who are blind due to retinitis pigmentosa (RP) or age-related macular degeneration (AMD)
  • Company 560 - Noninvasive tests for the risk assessment of cardiovascular disease and the detection of early-stage lung/breast/colorectal cancer
  • Company 561 - Guidewire system intended to safely/quickly cross occluded peripheral and coronary vessels
  • Company 562 - Matrix therapy based technology that treats skin ulcers/reduces amputation
  • Company 563 - Artificial muscle technology for the treatment of faecal and urinary incontinence
  • Company 564 - Technology that selectively treats only cancer cells and avoids destruction of normal cells
  • Company 565 - Full line of precision-crafted/disposable/ultra-minimally invasive surgical instruments
  • Company 566 - Beam steering/target tracking/treatment planning solutions to the external beam radiation therapy market
  • Company 567 - Device that uses combined electric field and low-intensity, noninvasive ultrasound for the treatment of solid tumors without the need for chemotherapy
  • Company 568 - One-shot, instantaneous anastomotic stapling devices for open AAA, EVAR, and CLI applications
  • Company 569 - Stent to treat cerebral/aortic aneurysms by modulating hemodynamic flow
  • Company 570 - Biomotion sensors that enable easy/non-contact capture of high-quality physiological data - remotely/wirelessly
  • Company 571 - Flexible/single-use/sterile video-endoscopes which may be used at the patient bedside and which avoid all cross-contamination risks
  • Company 572 - Therapeutic gene delivery to treat diabetes/obesity/intestinal disorders/hemophilia/anemia
  • Company 573 - Non-invasive technique for sampling the surface layers of the skin to generate individual genetic profiles for diagnostic/prognostics
  • Company 574 - Non-invasive method designed to only kill fat cells and not harm the skin or other tissue
  • Company 575 - 3-D/single-piece/dual optic accommodating intraocular lens (IOL)
  • Company 576 - Cellular therapy to act directly at the level of the cause of autoimmune disorders, the dysregulated immune regulation
  • Company 577 - Next-generation transluminally placed endovascular grafts for the treatment of aneurysmal disease in the AAA/TAA
  • Company 578 - Real-time endoscopic tissue imaging system for high-resolution visualization of bronchial/pulmonary tissue cross-sections without biopsy
  • Company 579 - Very strong/customizable/biomimetic/easily revisable artificial disc implant, requiring no assembly in situ
  • Company 580 - Diagnostic and therapeutic catheter-based devices for prevention/treatment of heart attacks caused by soft plaque
  • Company 581 - Advanced method of photocoagulation to provide more rapid, precise, and safe treatment for a variety of retinal conditions
  • Company 582 - Next-generation personal diagnostics for hematological malignancies/autoimmune disorders
  • Company 583 - Soft tissue repair/replacement, using proprietary chemistry and organic collagen matrices
  • Company 584 - Sirolimus-based product as a next-generation therapeutic for the treatment/prevention of wet AMD and the treatment of diabetic macular edema
  • Company 585 - Phototherapy/ultraviolet light to inactivate the organisms that cause nail infections
  • Company 586 - Technology enabling detection and monitoring wirelessly, remotely, and with no contact to the subjects; also through clothing/barriers
  • Company 587 - Biochips to identify gene expression patterns
  • Company 588 - Automated blood analysis at point-of-care
  • Company 589 - Applicator for breast brachytherapy that delivers targeted dose of radiation
  • Company 590 - MRI contrast agents to monitor the position/quantity of transplanted cells non-invasively in vivo
  • Company 591 - A soft tissue aperture fixation system for anterior cruciate ligament (ACL) reconstruction using the hamstring/other soft tissue grafts
  • Company 592 - Non-invasive/convenient measurement and monitoring of human hydration status, using saliva as a sample
  • Company 593 - Cryotherapy to ablate diseased tissue
  • Company 594 - Reliable/accurate/solid-state laser system for customized treatment of many vision disorders
  • Company 595 - Non-invasive/iontophoretic drug delivery system with broad applicability for treating serious ocular diseases
  • Company 596 - Electrical stimulation technology along with single-use disposables to restore continence control to individuals with abdominal ostomies/eliminate the need for traditional ostomy pouching systems
  • Company 597 - MRI-guided laser ablation system for targeted, minimally invasive, focal tumor therapy
  • Company 598 - Medical devices that enable earlier detection/minimally invasive treatment of lung cancer
  • Company 599 - Non-invasive devices for the treatment of superficial venous disease
  • Company 600 - Truly minimally invasive or open system utilizing a proprietary uni-axial screw at one-half the cost of poly-axial systems for all spine disorders
  • Company 601 - Catheter-based systems that will provide very rapid/selective hypothermia to various body organs and locations
  • Company 602 - Cardiac assist device for patients in moderate/severe long-term heart failure
  • Company 603 - Digital image acquisition, coupled with proprietary CAD decision-making algorithms, to provide an immediate/automated colposcopic evaluation
  • Company 604 - Robotic system for fabrication of nano-material based wound dressings, delivered on-demand, at the POC
  • Company 605 - Unique spine functional testing that delivers improved surgical outcomes
  • Company 606 - Electromagnetic thermal therapy to relieve pain/improve function in patients suffering from osteoarthritis
  • Company 607 - System to inactivate pathogens in all three major blood components: platelets/plasma/red cells
  • Company 608 - Therapeutic approaches to prevent the abnormal tissue growth that inhibits recovery from surgical procedures/impairs normal wound healing
  • Company 609 - Biocompatible shape memory polymers which can be programmed to change shapes/rigidity when an initiating stimulus is applied
  • Company 610 - A fully integrated, affordable, sample-to-result platform for rapid, accurate PCR-based detection/differentiation of infectious disease
  • Company 611 - Technologies that will prevent infection for many large patient populations
  • Company 612 - Light-activated drug therapy to transform cancer into a treatable chronic disease
  • Company 613 - 1-Percutaneous venous valve, 2-Inferior vena cava filter, 3-Multi-purpose/disposable laparoscopic scissor grasper, 4-Multi-sized/multi-stiffness guidewire
  • Company 614 - Non-invasive infrared imaging system for the early detection of breast cancer
  • Company 615 - Device for the treatment of sudden cardiac arrest for both in- and out-of-hospital markets
  • Company 616 - Line of antimicrobial coatings to prevent microbial colonization/biofilm formation of endotracheal tubes/other indwelling medical devices
  • Company 617 - 3-D tracking devices for use in surgical navigation and MIS
  • Company 618 - Implantable patient alerting system for the detection and prevention of heart attacks
  • Company 619 - Minimally invasive/RF nerve ablation to reduce of migraine headache pain
  • Company 620 - Less invasive devices for the treatment of glaucoma, intended to replace current therapies
  • Company 621 - Natural cell-based technologies to restore normal neuron function in the central nervous system
  • Company 622 - Non-invasive/urine-based diagnostic assays for specific cancer types
  • Company 623 - Fluid-controlled accommodating intraocular lens (IOL) to restore vision of youth to middle-aged/elderly individuals
  • Company 624 - Single, multi-cannula laparoscopic port and specially designed curved instrumentation
  • Company 625 - Technology that provides the precision of a scalpel and the bleeding control of traditional electrosurgery, without extensive collateral tissue damage
  • Company 626 - More viable/cost-effective method for treating intracranial aneurysms
  • Company 627 - System that enables consistent tissue contact/complete lesions during cardiac surgery for the treatment of arrhythmias
  • Company 628 - Non-invasive neurorehabilitation system
  • Company 629 - Cerebral protection system to prevent embolic strokes
  • Company 630 - Catheter-based drug delivery using high-frequency/low-power ultrasound
  • Company 631 - Technology for real-time identification/localization of cancer cell clusters to enable complete/residual-free therapeutic excisions
  • Company 632 - Third-generation cancer-associated biomarkers using proteomics
  • Company 633 - Cardiac mapping system that is non-invasive, maps the entire heart in one beat, and provides catheter localization
  • Company 634 - Repair and regeneration technology platforms designed to mend and regrow hard tissue (such as bone) and soft tissue (such as cartilage)
  • Company 635 - Minimally invasive/flexible spinal implant technology to treat vertebral compression fractures and degenerative disc disease
  • Company 636 - Catheter-based drug delivery system designed to dissolve blood clots in a single/rapid/one-step procedure
  • Company 637 - Rapid DNA-based point-of-care diagnostics
  • Company 638 - Joint prostheses as an adjunct to laminectomy/laminotomy/neural decompression/facetectomy, in lieu of fusion
  • Company 639 - Advanced trilobal pericardial valve technologies
  • Company 640 - Protective coatings for medical instrumentation to combat bacterial biofilms
  • Company 641 - Wireless ECG monitoring
  • Company 642 - De-cellularized biological scaffolds meant to function like native tissue
  • Company 643 - Non-invasive, wearable, watch-sized metabolism measurement system that employs the use of a low-cost proprietary disposable sensor using direct-calorimetry, to accurately measure minute-by-minute caloric expenditures
  • Company 644 - Advanced, intuitive real-time imaging for abdominal minimally invasive surgery
  • Company 645 - Technology that improves vascular access accuracy and visualization of veins and arteries as well as related vascular events such as rolled veins, bifurcations, vasospasm, and extravasation
  • Company 646 - Extracellular matrix derived from fibroblasts isolated from newborns (NO embryonic stem cells/animal products)
  • Company 647 - Next-generation cell-based/tissue-engineered products
  • Company 648 - Mesh wrap for permanent implantation around the heart to prevent/reverse the progression of heart failure
  • Company 649 - Handheld/breath-based blood glucose monitor
  • Company 650 - More targeted/accurate radiation of cancer cells with significantly fewer side-effects
  • Company 651 - Bioactive glass-ceramic material that offers whiter and less-sensitive teeth while protecting from tooth decay
  • Company 652 - Membrane optimization, coatings technologies, and development of polymers for biomedical applications
  • Company 653 - System to process/concentrate cellular components from autologous bone marrow, including adult stem cells, at the point-of-care and in just 15 minutes
  • Company 654 - Devices to control bleeding post-hysterectomy/in other cases of pelvic area trauma
  • Company 655 - Safe, non-invasive body shaping technologies
  • Company 656 - Non-invasive/fast/accurate diagnostic kits for: fertility, hormones, infectious agents, auto-antibodies, and tumor markers
  • Company 657 - Gene therapy products for the treatment of inherited/acquired diseases.
  • Company 658 - Stent technology for the treatment of atherosclerotic disease at/near bifurcations
  • Company 659 - Neo-organs/tissues derived from the patient's own (autologous) cells
  • Company 660 - Computer-controlled pressure garments for the effective treatment of lymphedema/chronic wound healing
  • Company 661 - Small/portable/disposable infusion pump kit to treat post-operative pain more effectively than narcotics
  • Company 662 - Pulsatile perfusion generator technology to greatly enhance the preservation time window and organ transplant quality
  • Company 663 - Second-generation electronic retinal implant to treat blindness due to retinitis pigmentosa
  • Company 664 - Device to improve drainage following heart, lung, and trauma surgery, as well as other procedures where drainage is critical
  • Company 665 - Next-generation/fully-automated/electronically-controlled/self-contained blood glucose system
  • Company 666 - Minimally invasive system for treating long-bone fractures using an intermedullary stent/cement
  • Company 667 - Non-invasive measurement of magnetic fields to diagnose functional brain disorders
  • Company 668 - Products to diagnose/treat dry and wet age-related macular degeneration (AMD) and other chronic diseases involving the alternative complement system
  • Company 669 - Wearable artificial kidney device
  • Company 670 - Multi-generational devices using hybrid technologies for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
  • Company 671 - Miniature patch that dispenses insulin
  • Company 672 - Microcatheter and imaging technologies for interventional ophthalmology
  • Company 673 - Transcutaneous yet needleless drug delivery system for the injection of drugs/vaccines in solid doses
  • Company 674 - Non-epigenetic cell reprogramming technology that enables the generation of patient-identical replacement tissue/organs on an as-needed basis
  • Company 675 - Device to percutaneously repair the mitral valve
  • Company 676 - Miniature intravascular flow augmentation device for every organ that needs temporary change of flow
  • Company 677 - Minimally invasive surgical procedure intended to reduce the incidence of stroke/thromboembolism associated with atrial fibrillation
  • Company 678 - Plaque vulnerability biomarkers to detect patients at risk for the development of stroke, myocardial infarction or claudication
  • Company 679 - A platform for minimally-invasive cardiac surgery (MICS) via single-port, subxiphoid access, and an endoscope that reaches any anatomical location, including complex paths, from one single access port
  • Company 680 - Percutaneous mitral valve replacement (PMVR) for Mitral Regurgitation (MR)
  • Company 681 - Medical devices for the osteoarthritis/rhinosinusitis markets
  • Company 682 - Miniaturized ultrasound probe that is easier-to-use/more flexible
  • Company 683 - Resonating sensor made out of piezoelectric ceramics that can be miniaturized and is suitable for use in diagnostic equipment
  • Company 684 - Bioresorbable peripheral/coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty
  • Company 685 - Disposable devices for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
  • Company 686 - True 3-D imaging to improve evaluation/planning of radiation treatments
  • Company 687 - Next-generation spinal implants
  • Company 688 - New unilateral posterior fusion technology
  • Company 689 - Products for nuclear replacement/augmentation, vertebral compression fracture repair, and spinal fusion
  • Company 690 - Second-generation, metal-on-metal cervical/lumbar artificial discs
  • Company 691 - Artificial cervical disc with controlled range of motion in all six degrees of freedom
  • Company 692 - Next-generation of biomaterials for spinal implants
  • Company 693 - Intradiscal arthroplasty device utilizing articulating PEEK-on-PEEK material
  • Company 694 - Hydrogel matrix with applications across multiple specialties
  • Company 695 - Intelligent microgels as injectable scaffolds for intervertebral disc repair
  • Company 696 - Minimally invasive disc augmentation system to repair/rehabilitate an intervertebral disc
  • Company 697 - Implant designed to retain motion following the removal of diseased disc and/or bone material in the upper spine
  • Company 698 - Tissue repair/surgical mesh systems for soft tissue repair
  • Company 699 - Silicon nitride implants with 3-D structured cancellous ceramic for strong capillary action
  • Company 700 - Tibial knee implant for stable fixation to the medial tibial plateau without bone cuts/cement/screws
  • Company 701 - Technologies to treat obstructive sleep apnea and snoring
  • Company 702 - Anatomically-driven/minimally invasive spinal products for motion preservation
  • Company 703 - Tissue engineering technologies for orthopedic/sports medicine patients
  • Company 704 - Real-time imaging/image guidance for the operating room
  • Company 705 - Stent that provides protection from embolic showers during/post-procedure
  • Company 706 - Minimally invasive vapor technology to treat emphysema
  • Company 707 - Human-based tissue scaffolds
  • Company 708 - Simple, low-cost infusion pump that contains the IV bag within it
  • Company 709 - Non-intrusive patient-monitoring systems that facilitate timely intervention for cardiac/respiratory deterioration
  • Company 710 - Bifurcated stenting
  • Company 711 - Bioabsorbable implants for accurate soft tissue fixation either to apposing soft tissue/to bone
  • Company 712 - Drug delivery vehicles that can easily be targeted to specific cell types/disease state tissues
  • Company 713 - Minimally invasive therapies for interventional neuroradiology
  • Company 714 - Treatment for ischemia via stem cell-based therapies
  • Company 715 - Cellular therapy device to treat liver disease
  • Company 716 - Customizable vibration therapy devices to stimulate bone/muscle tissue
  • Company 717 - Deep brain stimulation (DBS) guidance system
  • Company 718 - Cellular imaging technology, using the Internet to transfer real-time/secure/accurate cellular resolution images
  • Company 719 - Minimally-invasive percutaneous aortic valve replacement systems
  • Company 720 - Off-the-shelf implantable allograft tissue to support peripheral nerve repair and regeneration
  • Company 721 - Advanced detection, staging, endoscopic treatment and follow-up care for acute and chronic lung disease
  • Company 722 - Minimally invasive therapy for the treatment of chronic disc pain
  • Company 723 - A minimally invasive device for stomach-reduction surgery consisting of a stapling tool that can be passed down the throat into the stomach
  • Company 724 - Kidney stone management device and urethral dilating introducer
  • Company 725 - Ventricular elastic support therapy for heart failure
  • Company 726 - Plastic medical devices for gynecological exams and surgeries
  • Company 727 - Inferior vena cava filters
  • Company 728 - Neuromodulation system for both traumatic brain injury (TBI) and stroke
  • Company 729 - Minimally traumatic, bone- and cartilage-preserving knee implants and instrumentation
  • Company 730 - Radio-frequency (RF)-based tissue sealing and cutting instruments with a long jaw sealing length and high quality seal to greatly reduce procedure time and surgeon fatigue
  • Company 731 - Fast, accurate, and easy-to-use in vitro molecular diagnostic products that rapidly identify infectious pathogens
  • Company 732 - Unique spinal implant designed to promote rapid fusion
  • Company 733 - Devices for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
  • Company 734 - Unique transcranial magnetic stimulation system that allows direct non-invasive activation of deep brain structures
  • Company 735 - Dynamic "shape memory" platform to optimize mitral/tricuspid valve repair
  • Company 736 - Single molecule DNA analysis system, with no requirement for prior sequence information/PCR/cloning/probes
  • Company 737 - Biomaterials-based medical devices focusing on cardiovascular, metabolic, inflammatory, and fibrotic diseases
  • Company 738 - Transdermal/wound dressing/mucosal drug delivery
  • Company 739 - A unique solution similar to ring annuloplasty/edge-to-edge repair, all in one modality, for mitral valve repair
  • Company 740 - Minimally invasive devices that improve oxygenation for patients with COPD
  • Company 741 - Hands-free internal retractor/internally-anchored laparoscope camera cleaner
  • Company 742 - Particle technologies for the treatment/prevention of chronic respiratory disorders
  • Company 743 - Minimally invasive, single-procedure approach for the repair of cartilage damage/osteoarthritis
  • Company 744 - Biodegradable synthetic hydrogels for general and specialty surgery use
  • Company 745 - Silk-based biomaterial platforms for tissue rejuvenation/connective tissue repair
  • Company 746 - Ankle replacement implant for patients with chronic pain/arthritis
  • Company 747 - Biomarker assays for the early detection of cancer
  • Company 748 - 1-Painless intradermal drug delivery, 2-GERD diagnostic device, 3-Non-invasive continuous glucose monitoring
  • Company 749 - Detection products for viral/bacterial infections, genetic diseases, mutations, cancers, etc.
  • Company 750 - Video integration and equipment management system to enhance the MIS market
  • Company 751 - Multi-pixel x-ray source for enhanced system performance/new capabilities
  • Company 752 - Combination ultrasound/electrical stimulation device for skin rejuvenation
  • Company 753 - Bioprosthetic heart valve with a percutaneously-exchangeable leaflet set that provides lifetime service without anti-coagulation therapy
  • Company 754 - Advanced suturing technology for minimally invasive/NOTES/bariatric/cardiac/other surgical specialties
  • Company 755 - A minimally invasive electromagnetic navigation system for early detection of lung cancer
  • Company 756 - Patient-centric data system and analysis tools for translational medicine and research
  • Company 757 - Hand-held device to monitor post-operative/trauma patients for early warning signs of sepsis or infection in the bloodstream
  • Company 758 - Spinal cage with dynamic stabilization/MIS placement (3mm access) and easily revisable
  • Company 759 - Fully modular total hip replacement systems to reduce wear/add longevity
  • Company 760 - A \"plug & play\" system for treating non-invasive, curative, and palliative cancers and precursors
  • Company 761 - Products for the early detection of lung and oral cancers
  • Company 762 - System that performs a non-invasive, 30-second test to identify the risk of heart disease
  • Company 763 - Non-molecular bacterial screening, identification, and antibiotic susceptibility testing
  • Company 764 - Optical coherence tomography for evaluation of human tissue microstructure with real-time depth visualization
  • Company 765 - Wireless electronic skin patch sensors for the real-time measurement/monitoring/diagnosis/clinical management of cardiac arrhythmias
  • Company 766 - Non-fusion spinal solutions that control segmental motion/maintain the neutral zone simultaneously
  • Company 767 - Optical cell sorters used in stem cell/cell therapy treatments for cancer, autoimmune disease, and regenerative medicine applications
  • Company 768 - BQT®, a non-invasive point-of-care diagnostic test for osteoporosis and bone fracture risk
  • Company 769 - Low-mass PFO closure system capable of repairing the defect from within the tunnel
  • Company 770 - Third-generation biodegradable annuloplasty rings
  • Company 771 - Easy-to-use, instrument-free, disposable molecular diagnostic tests
  • Company 772 - 1-Bone cement to replace PMMA-based materials, 2-A liquid hydrogel wound dressing able to cure rapidly and in situ
  • Company 773 - Monitoring system to replace the manual assessment of labor progress with real-time/continuous information
  • Company 774 - Delivery of proteins and peptide drugs without burst, with near-zero order release, and with high bioavailability
  • Company 775 - Contrast agents/molecular imaging for detection using a modified porous Silicon (mpSi™) platform
  • Company 776 - New generation of high-power/compact lasers for cosmetic, dermatology, pain management, and wound applications
  • Company 777 - SutureCross™: Knotless Anatomic Fixation System for double row arthroscopic rotator cuff repair
  • Company 778 - Biodegradable surgical adhesive for seroma reduction in plastic surgery
  • Company 779 - Miniature blood pump, designed to be placed superficially like a pacemaker, for the long-term treatment of chronic heart failure (CHF)
  • Company 780 - Devices that use bio-electric stimulation therapy (bio-current) to treat hard-to-heal wounds
  • Company 781 - Minimally invasive catheter-based ablation technologies to treat atrial fibrillation and other cardiac arrhythmias
  • Company 782 - Transvaginal, ultrasound image-guided HIFU device, capable of real-time guidance and monitoring of therapy
  • Company 783 - A portable breath collection apparatus (BCA) which can collect breath samples virtually anywhere, for highly sensitive laboratory analysis
  • Company 784 - Automatic tools to support image visualization, lesion detection and quantification, temporal evolution assessment, and automatic reporting in chest and abdominal CT scans
  • Company 785 - RNA-based therapeutics
  • Company 786 - Wireless seizure alarm systems for people with epilepsy
  • Company 787 - Arm training device to restore arm movement in stroke patients who have experienced arm paralysis
  • Company 788 - Ophthalmic formulation of mitomycin-C in a single-use kit, for use in the surgical treatment of glaucoma
  • Company 789 - Products to diagnose the risk for heart attacks by means of assessing endothelial function
  • Company 790 - Minimally invasive medical devices for patients who are at risk for or have suffered a stroke
  • Company 791 - AOKit™-bio: an adaptive optics kit for biologists which enhances microscopic imaging
  • Company 792 - Neowater®, a water-based nanotechnology which has physical properties that mimic intracellular water
  • Company 793 - Metabolomic profiling of biomarkers for the diagnosis of early forms of dementia and neurodegenerative diseases
  • Company 794 - A portable oxygen delivery and ventilation system
  • Company 795 - Interventional bronchoscopy devices for lung diseases
  • Company 796 - Advanced endotracheal tube for intubation, fitted with advanced fiberoptic visualization technology
  • Company 797 - Modular hip stem technology and total knee replacement systems
  • Company 798 - First viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (\"CHF\")
  • Company 799 - Fusion and non-fusion spinal implants
  • Company 800 - A device that seals blood vessels after hemodialysis as an alternative to central venous catheters for kidney-dialysis patients
  • Company 801 - Non-invasive ultrasound body contouring
  • Company 802 - Non-invasive, painless, Navigated Brain Stimulation (NBS) for brain diagnostics and therapy
  • Company 803 - Noninvasive breast cancer risk assessment device
  • Company 804 - Low cost, easy-to-use, credit-card-sized devices which will allow on-the-spot quantitative diagnosis
  • Company 805 - Telemedicine paired with state-of-the-art ophthalmologic imaging
  • Company 806 - Devices for treating cardiovascular disease
  • Company 807 - Precision surgical systems for computer-assisted 3D planning, surgical navigation, and surgeon-controlled robotic surgery
  • Company 808 - Female sterilization technology
  • Company 809 - Electromedical/electrotherapeutic equipment
  • Company 810 - Products for the minimally invasive repair of long bone fractures
  • Company 811 - Molecular diagnostic products for laboratories that are intended to enhance medical care by providing early diagnostic information rapidly
  • Company 812 - New pulmonary drug delivery system
  • Company 813 - Next-generation laser therapy
  • Company 814 - Devices for the in-office polypectomy/myomectomy market
  • Company 815 - Low-cost, fast, and accurate molecular diagnostic products
  • Company 816 - EXPANSE Vertebral Body Replacement Device for use in the thoracolumbar spine
  • Company 817 - A software based thermal mapping system that will be used in conjunction with CT and planar x-ray imaging systems
  • Company 818 - Minimally invasive, single-use, disposable devices that enable incisionless, transoral procedures for the treatment of a number of upper gastrointestinal problems, including gastrointestinal reflux disease (GERD) and failed bariatric surgery
  • Company 819 - Mobile phone-based data collection for chronic disease management
  • Company 820 - Advanced gene expression and DNA quantification products and services
  • Company 821 - Optical backscatter technology to improve the way cancer is detected and diagnosed
  • Company 822 - Laser, light-based, and radiofrequency devices for aesthetic and medical applications
  • Company 823 - Diagnostic methods using microarray gene expression profiling to determine specific properties of tumors
  • Company 824 - Catheter-based devices which rapidly provide quantitative data to the physician about vessel and stent size, suitable for peripheral and cardiac applications
  • Company 825 - Advanced wheelchair technologies
  • Company 826 - Human bionic devices that can instantaneously interact with the human body to replace or restore biomechanical or physiological functions
  • Company 827 - Cell-based epicardial patch designed to promote blood vessel growth in ischemic cardiac tissue
  • Company 828 - Methods for treating human tissue based on volumetric bipolar radio frequency ablation (RFA), and surface ablation of tissue
  • Company 829 - Infusing normothermic fluids from 10mL/hour-1200mL/minute with 30-second setup through a disposable cassette
  • Company 830 - Technology using opto-acoustics for functional imaging/cancer diagnosis
  • Company 831 - High-intensity focused ultrasound in a catheter to treat atrial fibrillation
  • Company 832 - 1-Alternative to instrument-based viscosity testing; 2-A disposable blood to plasma device for use in micro-fluidic assays; 3-A home-use test for clotting time
  • Company 833 - Portable, easy-to-use consumer device that allows for easy, safe and green disposal of used insulin syringes, lancets and pen needles by vaporizing the sharp
  • Company 834 - Site-specific catheter-guided system to deliver drugs and biologics directly to the adventitia
  • Company 835 - Device based therapy targeting ischemic brain stroke and chronic heart failure
  • Company 836 - Integrated wireless monitoring
  • Company 837 - Non-invasive robotic radiosurgery system for cardiac ablation
  • Company 838 - Ceramic components for spine, orthopaedic, and other implant needs
  • Company 839 - Target-specific recombinant human protein focused on spinal fusion surgery
  • Company 840 - Patient controlled analgesia device for pain management
  • Company 841 - Less invasive orthopaedic implant solutions employing advanced pliable structured materials and innovative designs
  • Company 842 - Dual function, automatic, handheld sinus irrigator and aspirator for OTC consumer use
  • Company 843 - Computer-integrated robotic instrumentation/navigation tools for orthopedic surgery
  • Company 844 - Next-generation disposable colonoscope incorporating diagnostic/therapeutic capabilities allowing for a potentially sedation-less treatment
  • Company 845 - Total hip replacement system that addresses resistance to wear and resistance to dislocation with ceramic and double mobility
  • Company 846 - Percutaneous mitral valve replacement system for treatment of mitral regurgitation
  • Company 847 - Non-invasive continuous glucose monitoring device, for patients with diabetes, based on a multi-sensor platform
  • Company 848 - Growth factor and biomaterial addressing the needs of spinal fusion, osteochondral defects, osteoarthritis, dental medicine, and other indications
  • Company 849 - Open-sky, cryogen-free, superconductive MRI scanner that uses a U-shaped magnet with no barriers in between the patient and the environment for orthopaedic, general purpose, and interventional applications
  • Company 850 - Minimally invasive retractors for pelvic surgery to optimize pneumoperitoneum pressure and patient position (OP5)
  • Company 851 - Handheld device which measures the amount of calories a person requires to maintain body weight
  • Company 852 - Intelligent nasal drug delivery devices for topical, systemic and nose-to-brain applications
  • Company 853 - Developing a fully implantable extra-aortic counterpulsation device designed to provide long-term, cost-effective treatment and significantly improve quality of life for heart failure patients
  • Company 854 - An absolutely non-invasive, radiation- and side-effect free electro physiological high speed cardiac diagnostic system to identify upcoming heart attacks and sudden cardiac deaths
  • Company 855 - DART is utilizing an interstitial radiation source that by nuclear decay recoil mechanism emits high-energy alpha particles widely dispersed by diffusion and by convection in the tumor mass
  • Company 856 - Producer of surgical devices including a self-attaching hernia patch, anti-clog surgical drain, and cavity implosion device
  • Company 857 - Non-surgical serum based cure, proven effective for PAD, Diabetic and Cardiovascular disorders
  • Company 858 - Portable and networked medical devices such as handheld ultrasounds
  • Company 859 - Single-use rigid endoscopes, with superior image quality, at a reduced per-use cost
  • Company 860 - Providing private and hospital-based OB/GYNs, Perinatologists, and Radiologists with integrated reporting and image management systems
  • Company 861 - Minimally invasive ophthalmic device therapy for Dry Macular Degeneration and other blindness causing diseases
  • Company 862 - Minimally invasive surgical technology that uses ionizing radiation to treat wet age-related macular degeneration (AMD)
  • Company 863 - An automated blood glucose monitor for the intensive care unit using near infra-red spectroscopy
  • Company 864 - Human Globin, a biopolymer to replace animal collagens in dermal fillers and create biomaterials for tissue repair
  • Company 865 - Indigo Orb, Inc is a technology leader in "Automatic Detection of Epidural Cavity"
  • Company 866 - Developing and marketing EEG systems, tools and services for Neurologists, Neurosurgeons, and Neuroscience Researchers
  • Company 867 - Orthopedic products, specifically for upper and lower extremity small bone applications
  • Company 868 - Lumbar system for dynamic stabilization without fusion, artificial discs, and minimally invasive surgery systems
  • Company 869 - Reintroducing CHYMOPAPAIN, the only proven minimally-invasive therapy for herniated discs; it allows nuclear regeneration.
  • Company 870 - 1-Lumbar cage with integrated fixation screws, 2-Pedicle screw product line, 3-Access systems and implants for use in minimally invasive surgery (MIS)
  • Company 871 - Surgical adhesives that serve to augment or replace sutures and staples/tacks
  • Company 872 - Revisable cervical and lumbar total disc replacement that can be converted to fusion
  • Company 873 - Motion preservative artificial disc
  • Company 874 - Disc Motion Technologies has developed the first posterior lumbar arthroplasty system consisting of an artificial lumbar disc and a posterior dynamic stabilizer.
  • Company 875 - Building on an exclusive intellectual property platform for both fusion and non-fusion products
  • Company 876 - Tumor necrosis factor alpha (TNF-a) inhibitor therapy for treatment of chronic persistent radiculopathy (including sciatica) related to disc herniation.
  • Company 877 - Spinal implants, cervical, thoracolumbar, interbody, bone substitutes, motion preservation
  • Company 878 - Biocellulose technology that eliminates the risks/complications/limitations inherent in animal, human, and synthetic biomaterials
  • Company 879 - Wireless patient vital signs monitoring
  • Company 880 - Disease management system for early detection of heart failure using a noninvasive cardiovascular-sleep prognostic marker
  • Company 881 - 1-Soft tissue attachment nanotechnology, 2-Bioactive/biocompatible/osteoconductive synthetic bone filler, 3-Biodegradable fiberglass fiber & composites
  • Company 882 - Noninvasive blood glucose monitor that will measure glucose in sweat in a disposable dermal patch
  • Company 883 - Affordable thermal systems that are portable, easy-to-use, and comfortable to wear
  • Company 884 - High Intensity Focused Ultrasound for incisionless male surgical sterilization
  • Company 885 - Ambulatory infusion pumps and disposables that require no programming and use pre-filled solution containers
  • Company 886 - ViaDerm - home use transdermal drug delivery system creating microscopic passageways in the top skin layer
  • Company 887 - Tools for enabling adult stem cell based regenerative medicine
  • Company 888 - Lectin-based cell adhesion technology which enables stents that traffic cells in the bloodstream
  • Company 889 - Programmable lab-on-a-chip platform for applications ranging from drug discovery to consumer diagnostics
  • Company 890 - Technology that enables real-time tracking of the position and orientation of any interventional tool - biopsy device, catheter, endoscope, ablation probe, marker dispenser, etc.
  • Company 891 - Blood tests for: breast cancer/Alzheimer\'s disease/women\'s cancers
  • Company 892 - Spinal implants utilizing elastomeric polymers for non-fusion treatment of disc degeneration
  • Company 893 - ECG software for assessing acute ischemia and cardiac safety surrogates in clinical trials
  • Company 894 - Resorbable pegylated hydrogel for surgical wound sealing/adhesion prevention/sustained and targeted drug delivery
  • Company 895 - The Sensation
  • Company 896 - Robot-assisted stroke therapy devices
  • Company 897 - Endothelial management - less trauma combined with new agents for improved healing in vascular interventions
  • Company 898 - Digital Pulse Analyzer - provides early detection of arterial wall stiffness and biological age of arteries
  • Company 899 - Diagnostic platform with a test for measuring unbound Bilirubin for the management of newborn jaundice
  • Company 900 - Percutaneous light activation reduces intra-abdominal fat, returning Type 2 diabetic patients towards normoglycemia
  • Company 901 - 1-Cartilage implant for the knee, 2-Injectable cell therapy for the spinal disc/nucleus, 3-Bone graft extender to treat spinal deformities
  • Company 902 - Protein free induction of endochondral ossification, no human origin, not contagious, no soft tissue ossification
  • Company 903 - 1-Instant-on/instant-off proximal occlusion funnel catheter, 2-Scoring balloon with drug delivery capability
  • Company 904 - An internal adhesive biotechnology designed for strength, biocompatibility, and ease-of-use with applications in cardiovascular surgery
  • Company 905 - Technology that prepares the spinal disc for a nucleus replacement/minimally invasive fusion device
  • Company 906 - Tissue repair devices exploiting shear force transfer and large-interface substrates for adherent new tissue formation
  • Company 907 - Advanced skin biopsy and wound healing solutions to dermatology, cosmetic, primary care, and oncology clinicians
  • Company 908 - Advanced optical systems/services that are changing the way doctors evaluate and treat the eye
  • Company 909 - Non-invasive cardiac output monitoring to assess stroke volume, contractility, cardiac output, cardiac index, and thoracic fluid content
  • Company 910 - 1-Cardiovascular-directed growth factor therapeutics; 2-Endovascular catheter-based system to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events
  • Company 911 - A drug delivery platform that approaches the endovascular bifurcation challenge from a completely different angle
  • Company 912 - A bioactive ceramic that delivers better/faster spine fusion and bone repair
  • Company 913 - Percutaneously delivered implantable system to treat mitral valve regurgitation and improve congestive heart failure
  • Company 914 - Next-generation biomaterials technology
  • Company 915 - Noninvasive medical device for the treatment and prevention of obesity using controlled hypoxia
  • Company 916 - An implantable ophthalmic device to treat vision correction associated with Age-Related Macular Degeneration (AMD)
  • Company 917 - Accommodating and multifocal phakic IOLs, CE-approved for $ billion refractive IOL market
  • Company 918 - Biocompatible polymer implant to prevent or reverse the progression of chronic heart failure and mitral valve regurgitation
  • Company 919 - Noninvasive device used in the differential diagnosis of disc or facet mediated low back pain
  • Company 920 - Surgical stapling devices for open and laparoscopic procedures developed for the growing China market
  • Company 921 - PowerCosmetics micro-electronic patches, delivering skincare results faster and more effectively
  • Company 922 - IBraces - 100% customized, invisible orthodontic braces designed for efficient, effective treatment of teens and adults
  • Company 923 - Flash Ultrasound
  • Company 924 - Free-floating optical probe with multiple LD scanning and magnetic stabilization for noninvasive blood glucose monitoring
  • Company 925 - Repositionable/removable percutaneous heart valve, precision controlled delivery device, and calcified valve encapsulation system
  • Company 926 - Next-generation estrogen-based drug-eluting coronary stent and an orthopedics/sports injury pain management device
  • Company 927 - Heart pump that achieves superior flow and pressure performance, mimicking the physiological performance of the human heart, and reducing post-surgery kidney failure, mortality, and complications cost by 50%
  • Company 928 - Porcine-derived tissue devices for ligament, cartilage, bone, and soft tissue replacement and augmentation
  • Company 929 - MIS platform technologies for creating cavities in tissue and partially molding an orthopedic implant in situ
  • Company 930 - Orbital atherectomy for the treatment of peripheral vascular disease
  • Company 931 - Functional brain imaging centers that identify Alzheimer's, brain injury, stroke, ADHD, bipolar, depression, anxiety, OCD
  • Company 932 - A protein therapeutic biotreatment that regresses solid tumors and protects against relapses
  • Company 933 - Analyze, search, store, mine, share and unlock the power of digital tissue images
  • Company 934 - Smart devices to harness human physiology for health care, industrial safety, and law enforcement applications
  • Company 935 - Naturally-derived/non-crosslinked/collagen-based extracellular matrix to repair/remodel damaged tissues
  • Company 936 - Facet fixation system that is a less-invasive/faster alternative to pedicle screw fixation
  • Company 937 - Catheter-based technology for orthopedic trauma indications providing site-specific tissue drainage and drug delivery
  • Company 938 - Shielded reciprocating tissue sculpturing instrument, able to navigate into neural foramen to relieve nerve compression
  • Company 939 - 1-LIFEBACK® Spine Programs for non-operative and post-operative spine patients and 2-the LTX 3000® Rehabilitation System
  • Company 940 - Stable and extractable self locking intramedullary nails and proximal femoral fixation
  • Company 941 - Emperor Mobile Spinal Disc, P.E.E.K Cages, Pedicle Screw System, and Saturn Hip Resurfacing
  • Company 942 - Rapid table-mounted retraction/surgical site access for MIS placement of hip/knee/shoulder/spine implants
  • Company 943 - Lumbar dynamic stabilization with MIS compatibility and pedicle screws
  • Company 944 - Real-time image-guidance technology with an FDA-accepted accuracy claim of +/-1mm at 1 meter
  • Company 945 - Noninvasive, ambulatory, portable, 3-D traction technology providing an effective and unique therapy for spinal disorders
  • Company 946 - Fusion technology platforms and second-generation artificial discs for the lumbar and cervical spine
  • Company 947 - A biological and mechanical solution to annular repair and spine fusion
  • Company 948 - Low-profile implants/less invasive surgical instruments to treat spinal disorders utilizing fusion and non-fusion technologies
  • Company 949 - A CE-marked resorbable plating system for cervical fusions allowing for load sharing
  • Company 950 - Biomaterials-based product that augments or replaces the diseased nucleus pulposus of the spinal disc
  • Company 951 - Nitric oxide-based therapies to accelerate healing of tendon, bone, and other musculoskeletal tissue
  • Company 952 - Drug product for the treatment of acute spinal cord injury, cancer, macular degeneration, and glaucoma
  • Company 953 - Synthetic bone that duplicates the microstructure, composition, and performance of human bone
  • Company 954 - Implanted oscillating field stimulation device which regenerates acute and sub-acute damaged spinal cord nerve tissue
  • Company 955 - PuraMatrix injectable synthetic nanofibrous hydrogels for bone, cartilage and soft tissue regeneration, and drug delivery
  • Company 956 - Noninvasive device providing substitute vestibular sensory information through the tongue for treatment of balance disorders
  • Company 957 - Naturally occurring neuropeptide to treat ischemia associated with myocardial infarction, heart failure, and angina
  • Company 958 - Miniature/patient-controllable/valved catheter to improve quality of life/decrease urinary tract infections in patients suffering urinary retention
  • Company 959 - Phase-shifting technology for Contrast Ultrasound imaging
  • Company 960 - Medical devices, utilizing robust tyrosine-based resorbable polymer systems/pharmaceuticals in surgical barriers/cardiac rhythm management
  • Company 961 - Laparoscopic surgical access technology based on a No-Seal platform
  • Company 962 - Theramers
  • Company 963 - Respiratory diagnostics for noninvasive assessment of airway acidification in Asthma, COPD, and GERD
  • Company 964 - A "preventative" vaccine for HIV-AIDs
  • Company 965 - Post-proteomics multiplexed MS-based diagnostics/theranostics linked to drug development and personalized medicine
  • Company 966 - Image-guided therapy for metastatic liver disease
  • Company 967 - Biomaterial that regulates resorbability and enhances bone regeneration
  • Company 968 - Drug/device products for post-operative pain and orthopedic drug delivery indications using syntinate synthetic absorbables
  • Company 969 - Ultrasonic medical devices for minimally invasive therapeutic procedures for treatment of cancer/other healthcare purposes
  • Company 970 - Multi-channel implantable microelectrodes for deep brain stimulation and recording, enabling enhanced neuromodulation therapies
  • Company 971 - Aesthetic treatment device using collimated high-energy light and laser, delivered simultaneously by fiber delivery system
  • Company 972 - A remotely controlled, wireless-powered implantable 230-channel nerve stimulator built on a 15
  • Company 973 - Real-time, noninvasive monitoring of blood loss, anemia, and other vital blood measurements
  • Company 974 - Small/portable/handheld device for diagnosing brain hematomas
  • Company 975 - Fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify lipid rich plaques in the coronary arteries
  • Company 976 - Laparoscopic surgeons maintain direct control of the laparoscope movement/placement with GMP's Laparocision
  • Company 977 - Rapid testing systems led by the Growth Direct
  • Company 978 - Noninvasive mechanical compression for treatment/prophylaxis of lower extremity circulatory disorders such as: PAD/DVT
  • Company 979 - Ultraviolet light technologies for the inactivation of RNA viruses in/out of the body
  • Company 980 - Minimally invasive percutaneous neuromodulation pain therapy
  • Company 981 - The Axya Shoulder Fixation System generates ultrasonic energy for knotless suture welding in shoulder surgery
  • Company 982 - Gene-based products for the diagnosis and treatment of spinal disorders
  • Company 983 - A platform aerosol drug delivery nebulizer device for multiple- and single-use applications with disposables
  • Company 984 - Non-invasive continuous measurement of tissue oxygenation for various intraoperative and post-operative applications
  • Company 985 - Vascular stents and grafts with increased patency by improved flow dynamics, reducing stenosis and restenosis
  • Company 986 - Next-generation bio-medical adhesive, used as a filler for aneurysms in various areas of the body
  • Company 987 - SurfLink
  • Company 988 - Bifurcated coronary stent
  • Company 989 - Monitoring products based on microsensor technology allowing minimally invasive, real-time measurement of clinical chemistry parameters and therapeutic drug concentrations
  • Company 990 - Noninvasive, outpatient bariatric device for overweight/obesity
  • Company 991 - A suite of tools for automated CT Angiography (CTA) diagnostics for Coronary Artery Disease
  • Company 992 - Magnetically actuated telescopic intramedullary (IM) nail activated by an induced low power directional magnetic field
  • Company 993 - Transdermal delivery system of levodopa (L-DOPA) for the treatment of Parkinson's Disease
  • Company 994 - Immediate, active, device-less, and painless topical drug delivery, of small/macromolecules, for local/systemic indications
  • Company 995 - Endotracheal tube with video, self-locking orthopedic implants, structured TPN lipids, cell therapy for cancer, etc.
  • Company 996 - Products that digitize manual breast examination tissue elastic properties into objective computerized visual maps/reports
  • Company 997 - Technology for the manipulation of adult stem cells to repopulate chronically diseased liver tissue
  • Company 998 - Non-invasive airway clearance in ICU patients to prevent ventilator associated pneumonia
  • Company 999 - Unique add on and removable needle safety product that fits to standard glass/plastic syringes
  • Company 1000 - Medical devices utilizing radiofrequency and microwave energy which are cost-effective and clinically relevant
  • Company 1001 - Non-invasive screening of Peripheral Arterial Disease (PAD), combining postural/infrared blood volume testing
  • Company 1002 - Tissue fixation implants, injectable bone grafting biomaterials, and tissue scaffolds with drug releasing properties
  • Company 1003 - Miniature implantable, continuous blood glucose sensor for diabetics, incorporating noninvasive wireless monitoring
  • Company 1004 - Coronary guidewire, to provide real-time ultrasonic measurement of coronary arteries to determine stent size and apposition without exchange of catheters
  • Company 1005 - Bioabsorbable, bioactive, and drug-releasing medical device products for various fields of surgery
  • Company 1006 - 1- Interventional single-use cardiac support device and drug delivery platform, 2- Implants for use in/with magnetic resonance imaging (MRI) systems
  • Company 1007 - Endoscopically-placed devices to prevent GERD, obesity, and irritable bowel syndrome (IBS)
  • Company 1008 - Cellular implants for orthopedic, trauma, and spinal applications based on a biological form stable matrix
  • Company 1009 - SmartStep
  • Company 1010 - Dynamic optimization of pacing intervals according to hemodynamic sensors for CRT devices
  • Company 1011 - Neuro-monitoring systems for brain protection and stroke acute care in stroke units, cardiovascular ORs, during stenting, and in the ICU
  • Company 1012 - Medical devices that enable diabetes disease management and the prevention of lower extremity amputations
  • Company 1013 - Customized miniature disposable stereoscopic cameras that provide 3D vision, measurements, and image fusion in real-time
  • Company 1014 - Infusion catheter for treatment of tumors which are unresponsive to systemic chemotherapy by the local delivery of drugs and other agents
  • Company 1015 - Non-invasive imaging tool designed to provide automated, 3-D ultrasound images of the breast
  • Company 1016 - RFID hardware and software platform for test tubes/ apheresis device for blood component separation
  • Company 1017 - Saliva-based consumer diagnostic systems, which enable the development of personalized therapeutics
  • Company 1018 - Disposable, noninvasive, pump-less, and valve-less automatic blood pressure monitor "on-a-chip"
  • Company 1019 - Noninvasive neural vision enhancement
  • Company 1020 - Nanotechnologies for use in orthopedic implants, dental implants, and stents
  • Company 1021 - Specialty and standard electrophysiology catheters that have superior performance, advantageous features, and are affordable
  • Company 1022 - Dedicated angioplasty and stent systems for the treatment of arterial bifurcations
  • Company 1023 - System to ablate cardiac tissue as a means to potentially treat atrial fibrillation
  • Company 1024 - Point-of-care IVD platform that provides rapid, accurate, automated laboratory testing using low cost, disposable biochips
  • Company 1025 - Interventional MRI technology for cardiovascular imaging including detection/treatment of vulnerable plaque
  • Company 1026 - System analyzes a patient's susceptibility to cardiac arrest and consequent need for implantable defibrillator
  • Company 1027 - Patient recovery system for cosmetic and reconstructive surgery
  • Company 1028 - Microscope slide scanners and information management software that enable the digitization of pathology
  • Company 1029 - SutureLock - a versatile suture-securing knot-replacement device for endoscopic wound approximation
  • Company 1030 - Multi-Sensing Wireless Catheter platform attached along the GI-Uro tract detecting GERD, incontinence, and other abnormalities
  • Company 1031 - Noninvasive medical device providing low-risk hypoxic treatment that induces appetite suppression and weight loss
  • Company 1032 - Minimally invasive telemetric and continuous measurement of left atrial blood pressure at heart failure
  • Company 1033 - Catheter-based photoreactive treatment system for endovascular intervention in coronary and peripheral atherosclerotic disease
  • Company 1034 - Transcatheter mitral valve repair - will move mitral valve annuloplasty from a major open heart surgical procedure to a minimally invasive cardiac catheterization procedure
  • Company 1035 - A platelet reactivity test to measure the effect of anti-platelet drugs, particularly aspirin and Plavix
  • Company 1036 - OmniWave
  • Company 1037 - A portable laseroptical system for noninvasive differentiation between ischemic stroke and spontaneous intracerebral hemorrhages
  • Company 1038 - Alginate-based embolic material designed to fill blood vessel defects thereby displacing blood pressure effects and preventing vessel rupture
  • Company 1039 - A wearable continuous ultrafiltration device that removes fluid overload in patients with Congestive Heart Failure
  • Company 1040 - Minimally-invasive cardiac implantable devices for treating mitral valve regurgitation without atriotomy or cardiopulmonary bypass
  • Company 1041 - Surgical and percutaneous cardiac valve repair
  • Company 1042 - Percutaneous mitral valve repair simulating precision of surgical annuloplasty
  • Company 1043 - Pressure and flow sensing systems for vascular and other applications
  • Company 1044 - Advanced ECG-heart sound analysis to enable superior diagnosis/monitoring of CHF/ACS patients
  • Company 1045 - Minimally invasive interventional radiology/vascular surgery devices
  • Company 1046 - PeriVasc
  • Company 1047 - Perfusion monitoring for preventing septic shock, the greatest hospital mortality
  • Company 1048 - A noninvasive test for endothelial dysfunction using digital (fingertip) thermal monitoring
  • Company 1049 - Stentless aortic valve prosthesis to be delivered via catheter
  • Company 1050 - Catheter-based therapy which increases cerebral perfusion for the treatment of ischemic stroke and vasospasm
  • Company 1051 - Catheter-based devices to reconstruct the ventricle and downsize the heart volume
  • Company 1052 - Noninvasive device using muscular counter pulsation (MCP) technology for the treatment of chronic heart failure (CHF)
  • Company 1053 - 1-Bio-therapeutic designed from autologous stem cells and committed to a cardiac lineage before implantation, 2-Corresponding catheter for accurate transmyocardial injection
  • Company 1054 - Minimally invasive device-based technologies targeting the treatment of hemodynamic instability and perfusion
  • Company 1055 - Peptide-based therapeutic to enhance stent/graft patency
  • Company 1056 - Biomimetic coronary stent coating that prevents restenosis/reduces the need for extended courses of dual antiplatelet therapy
  • Company 1057 - Disposables for drawing blood -- percutaneous or from a catheter -- neonates to geriatrics
  • Company 1058 - Electrode sensor array, with integrated lead wires, simple, accurate and repeatable ECGs
  • Company 1059 - In vivo plasmapheresis and ultrafiltration to remove excess fluid from CHF patients in clinical trials
  • Company 1060 - Noninvasive therapeutic ultrasound to enhance perfusion for treatment of acute myocardial infarction
  • Company 1061 - Affordable handheld metabolic monitor (indirect calorimeter) with both medical and consumer weight management applications
  • Company 1062 - Unique microsphere-based technology for chronic/acute wounds
  • Company 1063 - Technologies that utilize flexible cross linking and sterilization processes which stabilize and sterilize biological tissue for use in orthopedic, wound, oral/dental, spine and neurological, breast, abdominal and thoracic applications
  • Company 1064 - Devices for mechanically induced bone growth, together with a "smart device" system for risk management
  • Company 1065 - Nitric oxide releasing surface treatments for enhanced biocompatibility in medical devices
  • Company 1066 - Automated implantable pump systems for moving fluids around inside the body
  • Company 1067 - Minimally invasive surgical access system used in laparoscopic surgery
  • Company 1068 - Long-term, miniature drug delivery implant with physician- controllable, zero-order release characteristics
  • Company 1069 - 1-Single-use, patented, disposable, hemorrhoid banding system; 2-Two-tier colon cancer diagnostic screen, Fecal Occult Blood Testing (FOBT)
  • Company 1070 - Interventional catheter-based system precisely measures stent and arterial size and cardiovascular repair tissue patch products
  • Company 1071 - Device for the treatment of mitral regurgitation and heart failure without requiring open heart surgery
  • Company 1072 - Light-based therapy for eradication of ulcer-causing Helicobacter pylori
  • Company 1073 - Non-invasive medical radar imaging for cardiopulmonary ambulatory monitoring and diagnosis
  • Company 1074 - Enteric Dialysis with Kibow Biotics - a food-grade microbial Gel cap formulation towards kidney failure applications
  • Company 1075 - IYIA has developed a proprietary, clinically effective device, O2Misly, for treating slow healing foot wounds, primarily diabetic foot ulcers
  • Company 1076 - Genetic and personal history based testing to predict age-specific risk of breast cancer diagnosis
  • Company 1077 - Controlled fluid delivery system for every medical application without batteries or power cords
  • Company 1078 - Non-contact intelligent medical vigilance for the hospital
  • Company 1079 - Capture and analysis of heart sounds leading to rapid and accurate diagnosis of cardiac pathologies
  • Company 1080 - Blood test that screens/diagnoses cervical cancer without need of a cervical exam/pap smear
  • Company 1081 - Implantable Left Ventricular Assist Device (LVAD) for heart failure
  • Company 1082 - Bioabsorbable drug eluting stents and stent coatings for treatment of vulnerable plaque and coronary stenosis
  • Company 1083 - Electronic pill for oral delivery of low bioavailability drugs
  • Company 1084 - Microsyringe delivery of cells, genes, and drugs to the vasculature/deep tissues of the body
  • Company 1085 - Percutaneous noninvasive heart valve replacement
  • Company 1086 - Molecular FingerPrinting process for early-stage diagnosis of cancer, enabling point-of-care therapeutics based on gene regulation
  • Company 1087 - Percutaneous access management system to provide early ambulation/eliminate major complications, leaving nothing behind in patient
  • Company 1088 - Totally implantable LVAD that does not interface with circulating blood
  • Company 1089 - Blood test for breast cancer measuring 5 protein biomarkers using super-sensitive ELISA with 95% accuracy
  • Company 1090 - Device for the treatment of Barrett's esophagus and prevention of esophageal cancer
  • Company 1091 - A device for the left atrial appendage for stroke prevention in patients with atrial fibrillation
  • Company 1092 - Noninvasive monitor to measure exhaled nitric oxide for the management of asthma
  • Company 1093 - Microplate-based electronic biosensor system for label-free, real-time cell based assays
  • Company 1094 - Interactive intraoperative CT scanning technology for image-guided interventions
  • Company 1095 - High Intensity Focused Ultrasound for minimally invasive thermal treatment of disc herniation without disc penetration
  • Company 1096 - Percutaneous systems to treat lower back pain
  • Company 1097 - Least invasive approach for the delivery of lumbar fusion and motion preservation therapies
  • Company 1098 - Telemeterized natural motion elastomer disc
  • Company 1099 - Interspinous process implant to treat Lumbar Spinal Stenosis (LSS)
  • Company 1100 - Clinical expertise, facility development, new technology, and business services including marketing and contracting
  • Company 1101 - Advance and commercialize less invasive spinal deformity surgical treatment without fusion
  • Company 1102 - Lumbar, thoracic, and cervical fusion devices including less invasive instrumentation; lumbar and cervical artificial discs
  • Company 1103 - Lumbar spine motion preservation via dynamic stabilization utilizing a semi-rigid rod and screw system
  • Company 1104 - 1-Stand-alone anterior lumbar IBF device and 2-Stand-alone cervical IBF device
  • Company 1105 - Compliant artificial lumbar disc with graduated modulus for restoration of normal spine biomechanics/enhanced durability
  • Company 1106 - 1-Synthetic alternatives to autograft/cadaver-based bone material, 2-Surgical hemostat as an adherent matrix/impermeable barrier to blood flow, 3-Bone augmentation material for injections in osteoporotic spines to treat vertebral compression fractures
  • Company 1107 - Orthopeutics, LP introduces Intrabrace a new non-surgical, injectable treatment for resisting spinal curvature in scoliosis.
  • Company 1108 - Bioactive synthetic bone graft substitute that is osteostimulative, osteoconductive, antimicrobial, and hemostatic
  • Company 1109 - Next-generation fusion, motion sparing, and minimally invasive spinal implant products
  • Company 1110 - Minimally invasive fusion system
  • Company 1111 - Fluidjet devices for open and MIS fusion, discectomy, artificial nucleus, and artificial disc procedures
  • Company 1112 - Osteogenica - bone marrow concentration system
  • Company 1113 - Dascor Arthroplasty System, spinal implants technology
  • Company 1114 - BioDisc, a nucleus replacement product based on an injectable, flexible, and durable protein hydrogel technology
  • Company 1115 - Second-generation, viscoelastic artificial disc restoring native function to the spine
  • Company 1116 - Three-dimensional surgical visualization technologies and expanding portfolio for digital surgical environment and digital healthcare network
  • Company 1117 - Real-time disposable stereotactic navigation devices for biopsy/targeted therapy compatible with CT, fluoroscopy, and MRI
  • Company 1118 - Minimally invasive cancer therapy using Magnetically Energized (ME) Thermotherapy
  • Company 1119 - Magneto-Optical Enantiomeric Detection (MOPED) for real-time, non-contact analysis of chiral pharmaceuticals
  • Company 1120 - First noninvasive, transcutaneous sensor array that continuously monitors peripheral circulation and/or core body temperature
  • Company 1121 - Disposable balloon cervical dilator for improved uterine access that decreases pain, avoids tearing and perforations
  • Company 1122 - Implantable encapsulated-cell technology for delivery of biological therapeutics to the nervous system
  • Company 1123 - Complete pre-configured system for implementing minimized cardiopulmonary bypass
  • Company 1124 - Catheter-based sealing of heart defects associated with stroke, migraine headaches, and other brain attacks
  • Company 1125 - Technology for imaging peripheral nerves in regional anesthesiology, pain management, and other markets
  • Company 1126 - Nanomagnetic particles enabling controlled drug delivery and elution for drug targeting and medical device applications
  • Company 1127 - MRI-compatible, precision- guided laser therapy for the treatment of brain tumors
  • Company 1128 - Implantable blood pump with magnetic levitation technology for patients suffering from heart failure
  • Company 1129 - Virtual Bone Biopsy MRI scanner add-on, allowing noninvasive imaging of bone microstructure for osteoporosis monitoring
  • Company 1130 - Precise miniature robotic technology for spine, knee, orthopedic, and neurosurgery minimally invasive procedures - SmartAssist
  • Company 1131 - Nanotechnology-based cancer therapy with contactless activation of tumor-specific nano-particles, adaptable to all solid tumors
  • Company 1132 - Point-of-care platform technology for assessing risk of cardiovascular disease and renal dysfunction
  • Company 1133 - Continuous blood gas monitoring and cardiac output measurement for the intensive care unit
  • Company 1134 - Non-blood contacting, active implantable direct cardiac compression device for the treatment of CHF
  • Company 1135 - Augmented reality simulators that train surgeons in the skills required for minimally invasive surgery
  • Company 1136 - Continuous, non-invasive glucose monitor for tight glycemic control at the hospital and at home
  • Company 1137 - ERBLAN MIS Surgical Devices allow safe entry into virtually any actual or potential anatomical space
  • Company 1138 - Technology that non-invasively measures/monitors mechanical heart function and disease utilizing a disposable brachial cuff
  • Company 1139 - Endovenous ablation system for varicose veins with 1320 nm CoolTouch laser
  • Company 1140 - Micro-porous ceramic wound treatment device that creates optimal conditions for normal wound healing
  • Company 1141 - Direct, real-time vision through flowing blood to guide therapy inside the heart and vessels
  • Company 1142 - Cath lab solution providing rapid onset of circulatory support in patients with acute heart failure
  • Company 1143 - Magnesium-based compound that will attach bone to bone and ligaments and tendons to bone
  • Company 1144 - AepEX auditory evoked potential depth of anesthesia monitor and aepEX-Fusion servo-controlled anesthesia delivery system
  • Company 1145 - Posterior dynamic stabilization device designed to support an injured or degenerated spine without eliminating motion
  • Company 1146 - Site-specific biological and drug delivery
  • Company 1147 - Noninvasive ultrasound-based tissue analysis services for early detection of malignant tumors
  • Company 1148 - Non-irritating dry electrodes now enabling long-term cardiac monitoring
  • Company 1149 - Non-incisional female sterilization
  • Company 1150 - Biopharmaceuticals targeting osteo-renal indications, including the complications of chronic kidney disease and dialysis, bone and cartilage repair and regeneration, and general dental and oral care
  • Company 1151 - Portable, compact, easy-to-use automated external defibrillators with full energy delivery and complete resuscitation solutions
  • Company 1152 - Rapid, point-of-care in vitro diagnostics
  • Company 1153 - Endoscopy systems allowing physicians to see very small, early-stage cancer and subtle pre-cancerous lesions
  • Company 1154 - Surgical instruments employing thermal welding technology to seal and cut tissue
  • Company 1155 - Minimally invasive disc replacement for chronic back pain
  • Company 1156 - A smart, communicating cigarette case, online support, and daily e-mails delivering an effective stop-smoking method
  • Company 1157 - A wireless personal emergency alert system that integrates with, and enhances, existing implanted medical devices
  • Company 1158 - Artificial total intervertebral disc capable of normal physiological movement and weight loading
  • Company 1159 - Catheters designed to diagnose, terminate, and treat cardiac arrhythmia during EP and ablation procedures
  • Company 1160 - Conservative Motion Preservation technology including minimally invasive facet joint replacement
  • Company 1161 - BioSilicon, nano-structured porous silicon for applications in drug delivery, diagnostics, tissue engineering, and orthopedics
  • Company 1162 - System that prevents embolic events by removing plaque and thrombus found in diseased arteries
  • Company 1163 - Bioresorbable polymer implants for use in a variety of orthopedics and spine surgical applications
  • Company 1164 - Liposomal formulation of recombinant IL-2 for use as chemotherapy or cancer vaccine adjuvant
  • Company 1165 - Helical stent providing enhanced abilities and flexibilities in drug delivery, scaffolding, and embolic protection
  • Company 1166 - Trabectome, an FDA-cleared, minimally invasive medical device technology for the treatment of open angel glaucoma
  • Company 1167 - A wireless, early detection and auto-alerting heart monitor system for outpatient and homecare markets
  • Company 1168 - Prevention of scarring caused by disease, medical intervention, or trauma via a beta emitting biopolymer
  • Company 1169 - Noninvasive, site-specific drug delivery technology to deliver compounds to the posterior segments of the eye
  • Company 1170 - Real-time, CT-guided, robotically controlled needle drivers for minimally invasive cancer therapy
  • Company 1171 - Automated, continual blood glucose monitoring for critically ill patients
  • Company 1172 - Molecular diagnostics based on patented, standardized, next-generation, multi-gene expression (StaRT-PCR) products and high margin services
  • Company 1173 - THERMOCEPS - a handheld, wireless device that stops bleeding during surgical procedures using focused, thermal coagulation
  • Company 1174 - Interventional catheter system for the mechanical recanalization of arterial chronic total occlusions quickly and reliably
  • Company 1175 - Portable automated critical care neuro instruments using advanced digital signal processing technology
  • Company 1176 - Monitor for autonomic nervous system displaying sympathovagal balance in real-time for diabetes/ anesthesia/cardiology applications
  • Company 1177 - Branched endografts for aortic disease
  • Company 1178 - Next-generation biomaterials using bioactive-ceramics technology platform
  • Company 1179 - Immunodiagnostics of placental recombinant markers to screen the risk of preeclampsia, preterm delivery, and IUGR
  • Company 1180 - Methods for eyebrow lifting, non-thermal loading of degradable matrices, and degradable implants
  • Company 1181 - Non-invasive modality for the treatment of insulin resistance/diabetic neuropathy
  • Company 1182 - Minimally invasive needle biosensor for in vivo glucose or lactate monitoring of intensive care patients
  • Company 1183 - P-15: a small peptide attachment factor for bone formation in orthopedics
  • Company 1184 - MIST Therapy using non-contact ultrasound to stimulate healthy cells allowing chronic wounds to heal
  • Company 1185 - Arthroscopic surgical devices
  • Company 1186 - Electronic device that closes the gap between drugs and surgery in osteoarthritis of the knee
  • Company 1187 - Cell-based therapy products for the treatment of heart failure secondary to myocardial infarction
  • Company 1188 - A five-carbon carbohydrate that increases cellular energy, improving cardiovascular health and tissue function
  • Company 1189 - Devices delivering infrared light to reduce pain and accelerate tissue healing
  • Company 1190 - Next-generation non-vascular interventional pulmonary and gastrointestinal stenting technology
  • Company 1191 - Artificial lung delivers O2 and removes CO2 through a catheter inserted into the vena cava
  • Company 1192 - Intravascular temperature management systems and catheters for cardiac and neuro intensive care patients
  • Company 1193 - Implantable devices for the endovascular treatment of hemorrhagic stroke
  • Company 1194 - Ultrasound catheters for targeted thermal ablation of tumors



Select the markets you wish to purchase for $499 each. If you wish to purchase more than 3 markets, your price will not exceed the price for Full Access $1,595.


























License Type:
Single User License 12 Months
Corporate License (Call, Email or
 for pricing)***


* "Multiple Market Access" includes existing content for each market selected plus regular updates within the selected market(s).
** "Full Access All 23 Markets" includes existing content for all 23 markets plus regular updates to all 23 markets.
*** Corporate License allows for multi-user and/or enterprise wide access.